

Sunday, July 27, 2025, AAIC Disclosures

8:00-8:45 am

1-2-FRS-D Novel in vivo models of neurodegeneration I

Selective cellular vulnerability to aging-related decline of proteostasis and tauopathy

Karen E Duff, PhD *has nothing to disclose.*

Wolframin-1-expressing neurons in the entorhinal cortex propagate tau to neocortical brain regions under the amyloid pathology influence

Seiko Ikezu, MD *has nothing to disclose.*

APOE4 to APOE2 'Switching' in the CNS vs Periphery: Differential Effects on AD Neuropathology

Lance A Johnson, PhD *has nothing to disclose.*

1-3-DEV Assessing the Legal and Ethical Risks of Biomarker Testing for Alzheimer's Disease in the Clinic: Driving Towards Solutions

Developing an Approach to Legal and Ethical Risks of Clinical Use of Biomarker Testing for Alzheimer's disease

Jalayne J. Arias, JD, MA *has nothing to disclose.*

Developing an Approach to Legal and Ethical Risks of Clinical Use of Biomarker Testing for Alzheimer's disease

Drew Blasco, PhD *has nothing to disclose.*

Developing an Approach to Legal and Ethical Risks of Clinical Use of Biomarker Testing for Alzheimer's disease

Annalise Rahman-Filipiak, PhD *has nothing to disclose.*

1-4-DEV Developing Topics on Real-World Data

Personalized Monitoring of Response to Anti-Amyloid Therapy in a Real-World Cohort using Clinical Assessment and Plasma Biomarkers

Christopher A Brown, MD, PhD *has nothing to disclose.*

Patient, Care Partner, and Health Care Professional Opinion of the Lecanemab Autoinjector for Subcutaneous Delivery in Early Alzheimer's Disease Patients

Daryl Jones, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai Inc., US - Employee/Owner

Real-World Clinical Practice of Lecanemab at PUMCH: Focus on Dynamic Imaging and Biomarker Evolution

Chenhui Mao, MD *has nothing to disclose.*

Monoclonal Antibody Administration in an Academic Institution and Private Neurological Practice: A Tale of Two Clinics

Michael Henry Rosenbloom, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai - Consultant/Advisory Board

1-5-LPR Imaging in neurodegenerative diseases

A Comprehensive Evaluation of Multiple Enlarged Perivascular Space Segmentation Tools

James D LeFevre, PharmD *has nothing to disclose.*

Characterization of MRI-derived atrophy subtypes using post-mortem MRI and neuropathological markers in Alzheimer's disease

Sophie E. Mastenbroek, MSc *has nothing to disclose.*

Head-to-head in vivo Braak staging with MK6240 and Flortaucipir

Andreia Rocha, PhD *has nothing to disclose.*

Sunday-397 Harmonizing visual readings of tau PET tracers - the HEAD study

Emma Ruppert, MD *has nothing to disclose.*

Sunday-400 ADprep – A Fully-Automated Software for Large-scale Multimodal MRI and PET Imaging Workflows

Amir Dehsarvi, PhD *has nothing to disclose.*

Sunday-410 Tracking structural changes in preclinical and prodromal Alzheimer's disease: insights from amyloid-beta pathology

Ting Qiu, MSc *has nothing to disclose.*

1-6-LPR From Early-Life to Late-Life: The Role of Social and Environmental Factors in Cognitive Aging

Association of neighborhood deprivation with Alzheimer's Disease pathologies, gray matter volume, white matter hyperintensities and cognition by sex, race or ethnicity and APOE4 status in Non-demented Older Adults

Pablo Aguilar, MSc *has nothing to disclose.*

Racial/ethnic identity, emotional support and late life cognition and cognitive decline after age 90

Kazi Sabrina Haq, PhD *has nothing to disclose.*

Predicting accelerated and delayed aging in global settings: biobehavioral age gaps and the role of global exposomes

Hernan Hernandez, PhD *has nothing to disclose.*

Changes in loneliness, social isolation, and social support and risk of dementia: a gender-disaggregated analysis of community-dwelling older adults

Htet Lin Htun, MBBS, MPH *has nothing to disclose.*

Early-Life Educational Experiences Moderates the Association Later-Life Glycemic Level and Memory Trajectories in Later-Life

A. Zarina Kraal, PhD *has nothing to disclose.*

1-7-FRS-D Neuropsychiatric symptoms and biomarkers I

Examining the Interaction of Alzheimer's Disease and TDP-43 Neuropathology, and Clinical Diagnosis on Neuropsychiatric Symptoms Burden

Adrienne L Atayde, MSc *has nothing to disclose.*

Efficacy and Safety of AXS-05 in Alzheimer's Disease Agitation: A Phase 3 Randomized Withdrawal Double-Blind Placebo-Controlled Study

George T Grossberg, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Acadia, Alkahest, Avanir, Axovant, Axsome Therapeutics, Biogen, BioXcel, Genentech, Karuna, Lundbeck, Otsuka, Roche, and Takeda - Consultant/Advisory Board

Acadia, Biogen, and Eisai - Speakers Bureau/Honoraria for non-CME

Anavex, EryDel, Intracellular Therapies, Merck, Newron, and Oligomerix. -

Axsome - Consultant/Advisory Board

BioXcel - Consultant/Advisory Board

Bristol Myers Squibb - Consultant/Advisory Board

Karuna - Consultant/Advisory Board

Lilly, Roche, and the National Institute on Aging - Grant/Research Support

Maplight Therapeutics - Consultant/Advisory Board

Neuropsychiatric Symptoms in Comorbid Alzheimer's Disease Neuropathologic Change and Frontotemporal Lobar Degeneration

Daliah Ross, PhD *has nothing to disclose.*

1-8-LPR Cognitive reserve and resilience

Exploring Emotional Well-Being in Exceptional Aging: Data from the SuperAging Research Initiative

Claire M. Alexander, PhD *has nothing to disclose.*

Capturing quality of education in cognitive assessments in diverse populations

Renelle Bourdage, MA, MSc *has nothing to disclose.*

Associations of lifecourse socioeconomic status and subjective cognitive decline as measured by the Everyday Cognition (ECog) among diverse older adults

Nancy X Chen, MPH *has nothing to disclose.*

The differential association of education with hippocampal volume and episodic memory in ethnoracially diverse adults aged 90 and older

Batool M. Rizvi, PhD *has nothing to disclose.*

Cognitive reserve as a moderator of the association between hippocampal volume and entorhinal thickness and later-life behavioral symptoms

Gurshaan Sidhu *has nothing to disclose.*

Sunday-516 Biomarker and cognitive associates of resistance to neocortical tau pathology in a pooled cohort

Colin Birkenbihl, PhD *has nothing to disclose.*

1-9-FRS-D Biomarker findings in global populations I

Characterizing blood-based biomarkers of AD pathology using both SIMOA and NULISA technologies among Indigenous Africans: Pioneering experience with the VALIANT Cohort

Tolulope O Akinyemi, MSc *has nothing to disclose.*

Alzheimer's disease plasma biomarkers in a global cohort: experience from the DAWN study

Anthony J Griswold, PhD *has nothing to disclose.*

Novel set of plasma proteins classifies Alzheimer's dementia in African Americans with high accuracy

Lindsey A. Kuchenbecker, BS *has nothing to disclose.*

9:00-10:30 am

1-11-FRS-A Dissecting molecular disease mechanisms: beyond APOE, Tau, Amyloid-beta

Novel Mouse Model of TDP43-opathy Demonstrates Paradoxical Effects of Aging on Neurodegenerative Phenotypes

Daniel W Fisher, MD, PhD *has nothing to disclose.*

Cell-Cell Interactions Associated with pTau Induced L2/3 Neuronal Loss in Alzheimer's Disease

Huan Li, PhD *has nothing to disclose.*

A human iPSC-derived neurosphere model to study functional and transcriptomic properties of microglial neuroprotection in AD

Ada J Lin *has nothing to disclose.*

Use of in vitro and in vivo models to test candidate Alzheimer's disease risk genes from GWAS

Edoardo Marcora, PhD *has nothing to disclose.*

Identification of regulatory networks involved in microglia subset specification

Marta Olah, PhD *has nothing to disclose.*

ABCA7 Loss of Function Variants Disrupt Neuronal Lipid Metabolism and Respiration

Djuna K Von Maydell *has nothing to disclose.*

1-12-FRS-B Untangling the relationship between neurodevelopmental disorders, cognitive decline, and Alzheimer's Disease risk.

Alzheimer's disease genetic risk dosage and verbal memory in autistic adults

Samantha A Harker *has nothing to disclose.*

Bridging neurodevelopment and neurodegeneration in genetic frontotemporal dementia and Alzheimer's disease

Suzee E. Lee, MD *has nothing to disclose.*

Preliminary findings and feasibility of mid-life cognitive and blood-based biomarker assessments in adults with and without prospectively studied ADHD diagnosis in childhood

Brooke Molina, PhD *has nothing to disclose.*

Examining Dementia Subtypes in a National Sample of Autistic Medicaid and Medicare Enrollees

Lindsay Shea, DrPH *has nothing to disclose.*

Reports of elevated cognitive decline in autistic adults are linked to high anticholinergic potency

Gregory L Wallace, PhD *has nothing to disclose.*

1-13-DEV Lecanemab Two Years Post-Approval: Real-World Case Series and Patient Pathway Learnings from Diverse US Clinical Settings

Physician Satisfaction With Lecanemab in Early Alzheimer's Disease: Real-World Insights From Prescribers in the United States

Gregory Cooper, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Davos Alzheimer's Collaborative - Grant/Research Support

Eisai - Speakers Bureau/Honoraria for non-CME

Eli Lilly - Grant/Research Support

Blood-Based Biomarkers in the Lecanemab Patient Pathway for Early Alzheimer's Disease in the United States

Cara Leahy, DO *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biogen - Consultant/Advisory Board

Eisai - Consultant/Advisory Board, Speakers Bureau/Honoraria for non-CME

Eli Lilly - Consultant/Advisory Board, Speakers Bureau/Honoraria for non-CME

Real-World Insights on the Lecanemab Patient Pathway in Early Alzheimer's Disease in the United States

Michael Henry Rosenbloom, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai - Consultant/Advisory Board

Real-World Use of Lecanemab in APOE ε4 Homozygotes and in Patients on Antithrombotic Therapy

Marwan N. Sabbagh, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alzheimer's Drug Discovery Foundation - Grant/Research Support

Athira, Lighthouse Pharmaceuticals - Ownership/Stock options

EIP Pharma/CervoMed -

Eisai, Lilly, Synaptogenix, NeuroTherapia, Signant Health, Novo Nordisk, Anavex, Cognito

Therapeutics, GSK, Abbvie, Alzheon. - Consultant/Advisory Board

Lewy Body Dementia Association - Grant/Research Support

National Institutes of Health (NIH) - Grant/Research Support

Real-World Use of Lecanemab With Consideration of Race, Ethnicity, and Geographical Diversity

Jose Soria-Lopez, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alzheimer's Association -

Alzheimers Association - Grant/Research Support

Aribio - Grant/Research Support

Arrowhead Pharmaceuticals - Speakers Bureau/Honoraria for non-CME

Biogen - Grant/Research Support, Speakers Bureau/Honoraria for non-CME, Consultant/Advisory Board

Eisai - Speakers Bureau/Honoraria for non-CME, Consultant/Advisory Board

Eli Lilly - Grant/Research Support, Speakers Bureau/Honoraria for non-CME

Genentech - Consultant/Advisory Board

Global Learning Collaborative - Speakers Bureau/Honoraria for non-CME

Karuna/BMS - Grant/Research Support

Merck - Consultant/Advisory Board

NIH-NIA - Grant/Research Support

Novartis - Grant/Research Support

The Neuron Clinic General Practice - Employee/Owner

Real-World Use of Lecanemab in Patients With Early Alzheimer's Disease in the United States: a Case Series Review

David C Weisman, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Acadia - Grant/Research Support
Acumen - Grant/Research Support
Alynlyam - Grant/Research Support
Alzheimer's Association - Grant/Research Support
Cereval - Grant/Research Support
Cognition - Grant/Research Support
Eisai - Speakers Bureau/Honoraria for non-CME, Grant/Research Support
Eli Lilly - Speakers Bureau/Honoraria for non-CME
Elil Lilly - Grant/Research Support
FDA - Consultant/Advisory Board
Lantheus - Consultant/Advisory Board, Speakers Bureau/Honoraria for non-CME
Maplight - Consultant/Advisory Board
MedTracker.com - Grant/Research Support
Novartis - Consultant/Advisory Board
Roche - Grant/Research Support
Sage - Grant/Research Support
Sanofi - Grant/Research Support
Serono - Grant/Research Support
Ventus - Grant/Research Support

1-14-PER-B Novel biomarkers for TDP-43 and alpha-synuclein

Alpha-synuclein in Different Genetic Subtypes of Parkinson's Disease

Adam Boxer *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alector - Consultant/Advisory Board
Alexion - Consultant/Advisory Board
Arrowhead - Consultant/Advisory Board
Arvinas - Consultant/Advisory Board
Biogen - Grant/Research Support
Eisai - Grant/Research Support
Eli Lilly - Grant/Research Support
Janssen - Consultant/Advisory Board
Merck - Consultant/Advisory Board
Neurocrine - Consultant/Advisory Board
Neurovanda - Ownership/Stock options
Novartis - Consultant/Advisory Board
Oligomerix - Consultant/Advisory Board
Ono - Consultant/Advisory Board
Oscotec - Consultant/Advisory Board
Regeneron - Grant/Research Support
Switch - Consultant/Advisory Board
Transposon - Consultant/Advisory Board

Novel insights into scalable biomarkers in frontotemporal dementia

Katheryn A. Q. Cousins, PhD *has nothing to disclose.*

miRNA 214 as a novel biomarker of microglial cytoplasmic TDP 43 aggregation

Seung Hyun Kim *has nothing to disclose.*

Biomarkers of alpha-synuclein pathology

Lucilla Parnetti, MD, PhD *has nothing to disclose.*

Diagnostic Biomarker Challenges and Opportunities in ALS

Philip C Wong, PhD *has nothing to disclose.*

1-15-PER-C Neurodegenerative diseases research and care on the African continent: A multidisciplinary Panel

Advocacy and Palliative Care as a Framework for Dignified Dementia Care in African Settings.

Zipporah Vunoro Ali, MD *has nothing to disclose.*

Environmental Considerations in Neurodegenerative Disease Etiology and Diagnosis

Hassan A. N. El-Fawal, PhD *has nothing to disclose.*

The Vascular Hypothesis of Dementia, including Alzheimer's Disease, and Risk Factors for VaD and AD in African Populations.

Raj Kalaria, DScM, FRCP, FMedSci *has nothing to disclose.*

Population-based socio-demographic platforms as a critical tool for contextual and equitable ADRD research in rapidly ageing African societies.

Stephen Tollman, PhD *has nothing to disclose.*

1-16-PER-C Mechanisms of neuropsychiatric symptoms in MCI and dementia

NPS in MCI: A scientometric analysis

Arisara Amrapala, PhD *has nothing to disclose.*

The role of NPS in the prediction of progression to dementia or reversion to normal cognition in MCI

Zahinoor Ismail, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

CADTH - Consultant/Advisory Board

EISAI - Consultant/Advisory Board

Lilly - Consultant/Advisory Board

Lundbeck/Otsuka - Consultant/Advisory Board

Novo Nordisk - Consultant/Advisory Board

Roche - Consultant/Advisory Board

Neural mechanisms of NPS in dementia

Olivier Piguet, PhD *has nothing to disclose.*

Associations between NPS and cognitive functions in dementia

Julietta M Sabates, BPsych(Hons) *has nothing to disclose.*

1-17-FRS-B Molecular Basis of Cognitive Resilience

Cellular signatures of vulnerability and resilience in Alzheimer's Disease brains

Gabriela Mantovani Baldasso, B.Sc. *has nothing to disclose.*

Molecular hallmarks of cognitive resilience and resistance in Alzheimer's disease: Insights from excitatory and inhibitory neurons

Isabel Castanho, PhD *has nothing to disclose.*

Interrogating conserved transcriptomic signatures of cognitive resilience in the frontal cortex

Lauren A Fish, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Bolden Therapeutics - Potent Holder/Royalties paid to you

Multi-domain cognitive resilience to Alzheimer's Disease, Lewy Body and TDP-43 neuropathologies

Tain Luquez *has nothing to disclose.*

Hippocampal Amyloid-Beta And Tau Distributions Differentially Affect Cognition In Centenarians

Susan K. Rohde, MSc *has nothing to disclose.*

1-18-FRS-A Proteomic signature prediction and mechanistic insights to cognitive decline

Predicting cognitive trajectories in asymptomatic individuals at-risk of AD: insights from a multi-platform plasma proteomics study

Federica Anastasi, PhD *has nothing to disclose.*

Plasma proteomics reveals novel protein signatures associated with dementia in chronic pain individuals: a prospective cohort study

Xiaoduo Liu *has nothing to disclose.*

Synapse Protein Signatures in Cerebrospinal Fluid and Plasma Predict Cognitive Maintenance vs Decline in Alzheimer's Disease

Hamilton Se-Hwee Oh, PhD *has nothing to disclose.*

Blood biomarkers of neuronal injury and glial cell dysfunction and 25-year cognitive decline and incident dementia in the ARIC study

Srishti Shrestha, PhD *has nothing to disclose.*

Proteomic Signatures of Dual Cognitive and Mobility Decline in Older Adults

Qu Tian, PhD, MSc *has nothing to disclose.*

Plasma proteome-wide analysis of dementia risk mechanistically implicates synaptic biomarkers

Keenan A. Walker *has nothing to disclose.*

11:00-12:15 pm

1-10-PL Plenary Session

Biomarker and clinical trajectories of preclinical AD

Sylvia Villeneuve, PhD *has nothing to disclose.*

2:00-3:30 pm

1-19-DEV Pathophysiology and Potential Mechanisms of ARIA

Complement-mediated vascular inflammation contributes to anti-amyloid mAb-induced ARIA in mice

Praveen Bathini, PhD *has nothing to disclose.*

ARIA: insights from human neuropathology

Delphine Boche, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alzheimer's Research & Therapy -

Alzheimer's Research UK - Grant/Research Support

Brain Tumour Research - Grant/Research Support

British Neuropathological Society - Grant/Research Support

Medical Research Council UK - Grant/Research Support

Pathological Society - Grant/Research Support

Neurovascular threats to brain health: implications for Abeta immunotherapy

Costantino Iadecola, MD *has nothing to disclose.*

Mouse models for studying anti-amyloid antibody-induced ARIA

Cynthia A Lemere *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Acumen Pharmaceuticals -

ADvantage Therapeutics - Consultant/Advisory Board

Alnylam Pharmaceuticals - Consultant/Advisory Board

Apellis Pharmaceuticals -

Biohaven Pharmaceuticals - Consultant/Advisory Board

Cyclo Therapeutics - Consultant/Advisory Board

Eli Lilly and Company - Consultant/Advisory Board

Kenes Group - Consultant/Advisory Board

Merck Pharmaceuticals - Speakers Bureau/Honoraria for non-CME

MindImmune Therapeutics -
Novo Nordisk -
Sanofi Genzyme - Speakers Bureau/Honoraria for non-CME
Switch Therapeutics - Consultant/Advisory Board

Investigating the Cascade of Immunological and Vascular Events in Amyloid Immunotherapy

Xavier Taylor, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eli Lilly - Employee/Owner

Investigating the role of MMP9 in anti-Abeta immunotherapy-associated ARIA

Donna M. Wilcock, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alzheimer's Association -

Longeveron - Consultant/Advisory Board

SynapsDx - Consultant/Advisory Board

Vigil Neuroscience - Consultant/Advisory Board

1-20-FRS-A Dissecting molecular disease mechanisms: APOE, Tau, Amyloid-beta

APOE4 alters vascular cells in cognitively normal brains and in vitro models revealing early pathogenic AD contributions of endothelial cells

Taylor Bertucci, PhD *has nothing to disclose.*

Micro-sub regional synapse weakening by mimicking the hyperphosphorylation of microtubule associated protein Tau in dendritic spines

Kei Kwangwook Cho, MD, PhD *has nothing to disclose.*

Fibrillar tau promotes endothelial dysfunction through RAGE signaling and AGEs production

Roberto A Guzman-Hernandez, BS *has nothing to disclose.*

Molecular Drivers of Regional and Cellular Vulnerability to Tau Pathology and Neurodegeneration

Ana C Pereira, MD *has nothing to disclose.*

Mitochondrial transport and axonal mitochondrial density in tauopathy neurons

ANUSRUTI SABUI, PhD (Pursuing) *has nothing to disclose.*

1-21-FRS-A Multimodal imaging and fluid biomarkers in Down syndrome

Distinct Sensitivity of MRI Versus [¹⁸F]FDG-PET To Detect Cerebral Changes Across the Alzheimer's Continuum in Down Syndrome: A Multimodal Imaging Study.

José Enrique Arriola-Infante, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Roche Diagnostics - Speakers Bureau/Honoraria for non-CME

Study of brain perfusion in adults with Down Syndrome along the Alzheimer's Disease continuum

Maria Franquesa-Mullerat, MSc *has nothing to disclose.*

Prediction of future tau accumulation and cognitive decline in Down Syndrome using plasma biomarkers

Shorena Janelidze, PhD *has nothing to disclose.*

Lower amyloid and small vessel disease in unimpaired older adults with Down syndrome

Patrick J. Lao, PhD *has nothing to disclose.*

Regional tau burden emerges following beta-amyloid chronicity timeline in the Down syndrome population

Max McLachlan *has nothing to disclose.*

The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI): Ten Years of Progress in Understanding Alzheimer's in Down Syndrome

Lidia Vaqué-Alcázar, PhD *has nothing to disclose.*

1-22-FRS-C Toward a new era of anti-amyloid antibodies: New mechanism of drug delivery and latest update on trontinemab

Interim biomarker results for trontinemab, a novel Brainshuttle™ antibody in development for the treatment of Alzheimer's disease

Gregory Klein, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

F. Hoffmann-La Roche Ltd - Employee/Owner, Ownership/Stock options

Latest results from the dose-expansion part (Part 2) of the Brainshuttle™ AD study of trontinemab in people with Alzheimer's disease

Luka Kulic, MD PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Next wave of innovation in Alzheimer's disease therapeutics: The value of novel active transport mechanisms

Catherine J. Mummery, MD PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alector - Consultant/Advisory Board

AviadoBio - Consultant/Advisory Board

Biogen - Grant/Research Support, Consultant/Advisory Board

Eisai - Speakers Bureau/Honoraria for non-CME, Consultant/Advisory Board

GSK - Consultant/Advisory Board

Immunobrain - Consultant/Advisory Board

Ionis - Consultant/Advisory Board

Lilly - Speakers Bureau/Honoraria for non-CME, Consultant/Advisory Board

MSD - Consultant/Advisory Board

Neurimmune - Consultant/Advisory Board

Novartis - Consultant/Advisory Board

Peerview - Speakers Bureau/Honoraria for non-CME

Prevail - Consultant/Advisory Board

Regeneron/Alnylam - Speakers Bureau/Honoraria for non-CME, Consultant/Advisory Board
Roche/Genentech - Consultant/Advisory Board
UCB - Consultant/Advisory Board
Wave Life Therapeutics - Consultant/Advisory Board

TRONTIER 1 and TRONTIER 2: Pivotal trials of trontinemab in early symptomatic Alzheimer's disease

Janice Smith *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

F. Hoffmann-La Roche Ltd - Ownership/Stock options
Roche Products Ltd - Employee/Owner

1-23-FRS-A Role of Alpha Synuclein in Alzheimer's Disease

Synergistic Neurodegeneration in Alzheimer's Disease with Lewy Body Co-Pathology: Insights from Deep Learning and CSF α -Synuclein Seed Amplification Assays

Abbas Babajani-Feremi, PhD *has nothing to disclose.*

Tau Cognitive Mismatch in Alzheimer's Disease Predicts Presence of Co-Pathology and Diverging Disease Trajectory

Christopher A Brown, MD, PhD *has nothing to disclose.*

Exploration Shared Pathological Mechanisms in Dementia with Lewy Bodies and Alzheimer's Disease Based on Serum microRNA Expression Profiling

Xin Ma, PhD *has nothing to disclose.*

A conditional two-step approach for detecting Lewy Body pathology: smell function testing and α -synuclein seed amplification

Sophie E. Mastenbroek, MSc *has nothing to disclose.*

Alpha-Synuclein Pathology in Down Syndrome-Associated Alzheimer's Disease: Insights from Seed Amplification Assay and Neuropathology

Íñigo Rodríguez-Baz, MD, PhD *has nothing to disclose.*

The Novel PET Radioligand [^{11}C]MK-7337 Detects Alpha-Synuclein Pathology in Parkinson's Disease Patients

Wang Yuchuan, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Merck & Co. - Employee/Owner, Non-Mutual funds Stock

1-24-PER-A Unravelling the Genetics, Biomarkers and Reducing the Burden of Dementia in Africa

Epidemiology of Dementia in Africa

Rufus O. Akinyemi, MBBS, MSc, PhD *has nothing to disclose.*

Leveraging African Ancestry Diversity for Global Advances in Alzheimer Disease Genetics

Anthony J Griswold, PhD *has nothing to disclose.*

Preliminary efforts in biobanking and plasma biomarkers by the African Dementia Consortium

Jean N Ikanga, PhD, MPH *has nothing to disclose.*

Enhancing Participant Recruitment and Retention in Dementia Research through Community Engagement

Michelle Nichols, PhD, RN *has nothing to disclose.*

Overview of session

Adesola Ogunniyi *has nothing to disclose.*

Advancing Dementia Risk Prediction and Prevention in Africa Through Precision Health Approaches

Chinedu T Udeh-Momoh, PhD *has nothing to disclose.*

1-25-FRS-A Neuropsychiatric Symptoms - Recognition and Implications

Impact of Neuropsychiatric Symptoms on Measures of Daily Functioning in Older Adults

Mark A. Dubbelman, PhD *has nothing to disclose.*

The measurement of agitation in neurocognitive disorders: A systematic review

Dylan X. Guan, HBSc *has nothing to disclose.*

Agitation – a case study highlighting the importance of the IPA criteria

Zahinoor Ismail, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

CADTH - Consultant/Advisory Board

EISAI - Consultant/Advisory Board

Lilly - Consultant/Advisory Board

Lundbeck/Otsuka - Consultant/Advisory Board

Novo Nordisk - Consultant/Advisory Board

Roche - Consultant/Advisory Board

Associations between mild behavioral impairment and amyloid deposition in amnesic mild cognitive impairment

Yu Kyeong Kim, MD, PhD *has nothing to disclose.*

Neuropsychiatric symptoms are associated with tau pathology in Autosomal Dominant Early Onset Alzheimer's Disease caused by *PSEN1* and *APP* mutations

Nancy E Ortega, MS *has nothing to disclose.*

Mild Behavior Impairment with Subjective Cognitive Decline is associated with impaired cognitive function

Carol A. Van Hulle, PhD *has nothing to disclose.*

1-26-FRS-A Role of genes and environment in risk and resilience of alzheimer's and related disorders

TOX-AD: Exposome Effects of the Environmental Neurotoxicants Lead, Cadmium, and Arsenic on Brain Metal-Metalloid Accumulation and Alzheimer's Disease Pathobiology

Leandro Ceotto Freitas Lima, PhD *has nothing to disclose.*

Common genetic variants in *HIVEP3* are associated with cognitive SuperAging in the Amish

Daniel A. Dorfsman, PhD *has nothing to disclose.*

Association of Neighborhood-Level Disadvantage with Cerebrovascular Disease Neuropathology in a National Sample of Brain Donors

Grace C George, PhD, MPA *has nothing to disclose.*

Gene-Environment Interactions in Late-life Cognitive Functioning: The Impact of Polygenic Scores and Early Life Trauma in African American Older Adults

Soohyun Park, PhD *has nothing to disclose.*

Coordinated multi-cellular responses to Alzheimer's disease pathology reveal sex-specific resilience signatures

Gabriele Vilkaite *has nothing to disclose.*

Tuesday-080 *RELN* SNP rs802787 protects against A β -driven tau pathology, counteracts *APOE* ϵ 4 effects, and slows cognitive decline in sporadic late-onset Alzheimer's disease

Giovanna Carello-Collar *has nothing to disclose.*

1-27-FRS-A Integrative Investigation of Alzheimer's Disease and Aging Through Imaging Genetics and Proteomics

Sex-specific patterns of a machine learning-derived Alzheimer's brain atrophy imaging signature in participants without diagnosed cognitive impairment: A multi-cohort study

Filippos Anagnostakis *has nothing to disclose.*

Genetically-informed parcellation reveals interpretable brain patterns and enhanced genetic associations in Alzheimer's Disease compared to structural-only approaches

Marilena De Pian *has nothing to disclose.*

Proteome-wide analyses of machine learning-based neuroimaging signatures reveal EFEMP1 and CXCL12 as determinants of neurodegeneration

Michael R. Duggan *has nothing to disclose.*

CSF and plasma proteomic insights into the pathophysiology of cerebral small vessel disease and cerebrovascular event risk prediction

Ines Hristovska, PhD *has nothing to disclose.*

White matter integrity measures relate to distinct CSF proteomic profiles in non-demented subjects dependent on amyloid status

Luigi Lorenzini, PhD *has nothing to disclose.*

Shorter leukocyte telomere length is associated with distinct CSF biomarker dynamics across early AD stages in at-risk individuals

Blanca Rodríguez-Fernández, MSc *has nothing to disclose.*

3:30-4:15 pm

1-A-GEP Guided Electronic Poster Tour: Technology-based nonpharmacological interventions for dementia in diverse settings: focus on meaningful outcomes

Sunday-629 Engagement and task satisfaction during cognitive stimulation tasks facilitated by a social robot versus a human research assistant

Monica Sanches Yassuda, PhD *has nothing to disclose.*

Wednesday-296 Vibration Sensing - A Novel Approach to Detecting Activities of Daily Living

Alyssa Weakley, PhD *has nothing to disclose.*

Wednesday-610 Evaluating the effects of technology-supported music-making on engagement for people living with dementia in community settings

Jennifer MacRitchie, PhD *has nothing to disclose.*

3:40-4:15 pm

1-B-GEP Guided Electronic Poster Tour: Vascular and Infectious Disease Contribution to Cognitive Impairment and Alzheimer's Disease and Related Dementias in Africa

Sunday-116 Improvements in cognitive performance switching from efavirenz- to dolutegravir-based antiretroviral therapy in South African people with HIV: the CONNECT study

Sam Nightingale, PhD *has nothing to disclose.*

Sunday-491 Vascular Dementia and Risk Factors in Ethiopia

Yared Z Zewde *has nothing to disclose.*

Sunday-531 Chronic HIV Infection Association with Cognition and ADRD Plasma Biomarkers in Uganda

Roslyn Valdespino, MPH *has nothing to disclose.*

Wednesday-730 Demographic and Contextual Variability in the Underdiagnosis of Dementia-Related Cardiometabolic Risk Factors in African Populations

Chinedu T Udeh-Momoh, PhD, FHEA *has nothing to disclose.*

4:15-5:45 pm

1-28-FRS-B Diagnostic Criteria: Alzheimer's Association Staging and Diagnosis Criteria and the International Working Group (IWG) Criteria. Discussion and Dialogue.

FDA Perspective on Diagnosis of Alzheimer's, including FDA Draft Guidance

Teresa Buracchio *has nothing to disclose.*

The Risks of Clinical Expression of Alzheimer's Disease (AD) in People with Biomarkers of Alzheimer's Pathology

Howard H. Feldman, MDCM, FRCP(C) *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Allyx Therapeutics - Grant/Research Support

Arrowhead Pharmaceuticals - Consultant/Advisory Board

Association for Frontotemporal Dementia -

Axon Neuroscience - Consultant/Advisory Board

Biosplice Therapeutics - Consultant/Advisory Board

Epstein Family Alzheimer's Research Collaboration -

Janssen Research and Development - Consultant/Advisory Board

LuMind Foundation - Consultant/Advisory Board

Novo Nordisk - Consultant/Advisory Board

Rainwater Charitable Foundation -

Roche/Genentech Pharmaceuticals - Consultant/Advisory Board

Royal Society of Canada -

Tau Consortium - Consultant/Advisory Board

Translating Research in Elder Care -

University of British Columbia - Potent Holder/Royalties paid to you

Vivoryon Therapeutics - Grant/Research Support

International Work Group (IWG): Alignment Across Criteria

Giovanni Frisoni *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Lilly - Consultant/Advisory Board

Novo Nordisk - Consultant/Advisory Board

Alzheimer's Association Workgroup: Alignment Across Criteria

Clifford R. Jack, MD *has nothing to disclose.*

Alzheimer's Disease Begins Years Before Symptoms: Alzheimer's Association Workgroup

Reisa A. Sperling, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Abbvie - Consultant/Advisory Board

Acumen - Consultant/Advisory Board

Alector - Consultant/Advisory Board

Apellis - Consultant/Advisory Board

Janssen - Consultant/Advisory Board

Roche - Consultant/Advisory Board

EMA perspective on Diagnosis of Alzheimer's

Steffen Thirstrup, MD, PhD *has nothing to disclose.*

1-29-FRS-A A Half Century of Tau

Biofluid-based biomarkers for tau pathophysiology in Alzheimer's disease

Kaj Blennow, MD, PhD *has nothing to disclose.*

Pharmacological targeting of tau-induced retrotransposon activation

Bess Frost, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Transposon Therapeutics - Consultant/Advisory Board

Tau Protein and Neurodegeneration

Michel Goedert, MD, PhD *has nothing to disclose.*

Alzheimer's Disease Trajectory and the In Vivo Anatomy of Tau Progression

Keith A. Johnson, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alzheimer's Association - Grant/Research Support

Merck - Consultant/Advisory Board

NIH/NIA - Grant/Research Support

Novartis - Consultant/Advisory Board

Mitochondrial NADK, a Novel Functional Mediator of Tau Toxicity in Alzheimer's Disease

Andrés Norambuena, PhD *has nothing to disclose.*

The Dual Role of Tau in Neuroprotection and Disease: Neuronal Senescence as a Therapeutic Target

Miranda E. Orr, PhD *has nothing to disclose.*

1-30-PER-C Use of biomarkers in an era with anti-amyloid treatment

Imaging Recommendations and Practice considerations for ARIA Monitoring

Petrice M Cogswell, MD PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai - Speakers Bureau/Honoraria for non-CME

Eli Lilly - Consultant/Advisory Board

Kaplan - Speakers Bureau/Honoraria for non-CME

Medical Learning Institute -

Medscape -

Peerview -

Using biomarkers to determine when to stop anti-amyloid treatment

Takeshi Iwatsubo, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai - Speakers Bureau/Honoraria for non-CME

Eli Lilly - Speakers Bureau/Honoraria for non-CME

Determining eligibility for anti-amyloid treatment

Barbara Joy Snider, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai - Consultant/Advisory Board

Eli Lilly - Consultant/Advisory Board

Hoffman La Roche - Consultant/Advisory Board

Using (digital) biomarkers for monitoring disease progression

Alina Solomon, MD, PhD *has nothing to disclose.*

1-31-FRS-A Anti-Amyloid Therapies in Clinical Practice: Real World Evidence and Implementation Consideration

Modeling amyloid therapy potential on a population level: An adaptation of the MISCAN-Dementia model

Chiara C. Brück *has nothing to disclose.*

Indirect Treatment Comparison of ARIA Outcomes for Lecanemab Compared to Donanemab Based on Reported Results

Anna Burke, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alector - Consultant/Advisory Board, Grant/Research Support

Cognito Therapeutics - Grant/Research Support

EIP Pharma - Grant/Research Support

Eisai - Speakers Bureau/Honoraria for non-CME

Lilly - Speakers Bureau/Honoraria for non-CME, Consultant/Advisory Board

Roche - Grant/Research Support

Clinical evidence and biological considerations in the clinical use of lecanemab – experience at an academic medical center.

Lawrence S. Honig, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Acumen - Grant/Research Support

Alector - Grant/Research Support

Alnylam - Grant/Research Support

Biogen - Consultant/Advisory Board

Cervomed - Grant/Research Support
Cognition - Grant/Research Support
Eisai - Grant/Research Support, Consultant/Advisory Board
Ferrer - Grant/Research Support
GSK - Grant/Research Support
Medscape - Consultant/Advisory Board
New Amsterdam - Consultant/Advisory Board
PPD - Consultant/Advisory Board
Prevail/Lilly - Consultant/Advisory Board
Roche - Consultant/Advisory Board
Transposon - Grant/Research Support
Vaccinex - Grant/Research Support
Vigil - Consultant/Advisory Board

Characteristics and Safety Outcomes of Patients Treated with Lecanemab or Donanemab in Routine Clinical Practice: A Nationwide Study

Jay B Lusk, MD, MBA *has nothing to disclose.*

Therapeutic Time Window of Disease-Modifying Therapy for Early Alzheimer's Disease

Saki Nakashima, MD *has nothing to disclose.*

Use of Lecanemab for Alzheimer's Disease within the Veteran's Health Foundation: Early Findings

Alison J. O'Donnell, DO, MPH *has nothing to disclose.*

1-32-FRS-A LATE and novel biomarkers

The MRI signature of LATE-NC-associated hippocampal sclerosis extends beyond the medial temporal lobe

Michel J. Grothe, PhD *has nothing to disclose.*

VeraBIND Tau test, a novel plasma assay for active tau pathology, identifies individuals with positive tau-PET signal, regardless of amyloid status

Bernard J Hanseeuw, MD, PhD *has nothing to disclose.*

Clinical usefulness of plasma p-tau217 and eMTBR-tau243 combination for diagnosis and patient stratification

Oskar Hansson, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eli Lilly - Employee/Owner

Specific atrophy patterns distinguish tau and TDP-43 pathology: a longitudinal MRI ante-mortem study

Yasmine Salman, PhD student *has nothing to disclose.*

Characterization of individuals fulfilling clinical criteria for limbic-predominant age-related TDP43 encephalopathy (LATE) in a tertiary memory clinic

Marie R. Vermeiren, MD *has nothing to disclose.*

Molecular signatures of LATE-NC: insights from transcriptomic analyses

Jijing Wang, PhD *has nothing to disclose.*

1-33-FRS-B Culturally appropriate cognitive assessment in Sub-Saharan Africa: learnings, challenges, and opportunities

Practical Feasibility of Digital Cognitive Assessments in Older Kenyan Adults

Kevin Kipkoech, MSc *has nothing to disclose.*

Are we measuring what we think we are measuring? The construct validity of a multi-domain cognitive test battery in older Kenyan adults

Rachel W Maina, MS.c, PhD *has nothing to disclose.*

Development, adaptation, and validation of a cognitive assessment battery harmonized with the National Alzheimer's Coordinating Centre's (NACC) Uniform Data Set (UDS) in Botswana

Lingani Mbakile-Mahlanza, DPsyc *has nothing to disclose.*

Adaptation and Validation of Brief Tablet-Based Cognitive Assessment Tool in Uganda

Jeremy A. Tanner, MD, MPH *has nothing to disclose.*

Designing Culturally Appropriate Cognitive Tools in Resource Limited Setting: Lessons from Ethiopia's Multilingual and Culturally Diverse Context

Yared Z Zewde *has nothing to disclose.*

1-34-FRS-B PsychAD Consortium: Unraveling Alzheimer's Disease and Neuropsychiatric Symptoms through Comprehensive Single-Cell Genomics

Population-scale cross-disorder atlas of the human prefrontal cortex at single-cell resolution

Jaroslav Bendl, PhD *has nothing to disclose.*

A single-cell transcriptomic atlas of the prefrontal cortex across the human lifespan

Kiran Girdhar, PhD *has nothing to disclose.*

Single-Nucleus Atlas of Cell-Type Specific Genetic Regulation in the Human Brain

Gabriel E Hoffman, PhD *has nothing to disclose.*

Single-cell atlas of transcriptomic vulnerability across multiple neurodegenerative and neuropsychiatric diseases

Donghoon Lee, PhD *has nothing to disclose.*

Phenotype Scoring and Personalized Analysis of Population-Scale Single-Cell Data Dissects the Complexity of Alzheimer's Disease

Daifeng Wang, PhD *has nothing to disclose.*

1-35-FRS-A Cognitive Reserve and Brain Resilience: The Role of Lifestyle, Diversity, and Early-Life Experiences in Aging and Dementia

Advancing Research on Diversity and Resilience in Aging and Dementia: Methodological Challenges and Roadmap Recommendations

Roger A. Dixon, PhD *has nothing to disclose.*

The role of sex, gender, and SSDH in resilience research

Gillian Einstein, PhD *has nothing to disclose.*

Associations Between Early/Current Neighborhood Deprivation and Midlife Cognitive Functioning: Results from the Colorado Adoption/Twin Study of Lifespan behavioral development and cognitive aging (CATSLife)

Elizabeth Muñoz, PhD *has nothing to disclose.*

The role of hormonal and reproductive events on cognitive aging in a cohort of female civil servants: The Whitehall II Study

Shireen Sindi, PhD, MBA *has nothing to disclose.*

Integrative Discussion: Clinical Importance and Applied Potential of including Diversity in Resilience Research

Prashanthi Vemuri, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

NIH - Grant/Research Support

Social, Physical, and Cognitive Activity Patterns and Their Association with Tau and Amyloid Resistance and Resilience

Daniel Willie-Permor, MD, MPH *has nothing to disclose.*

1-36-FRS-B Advances in Focused Ultrasound For Alzheimer's Disease: The Most Powerful Sound You Will Never Hear.

Extensive FUS BBBO to Improve Symptoms of AD

Jin Woo CHANG, MD *has nothing to disclose.*

Translational Research with FUS BBBO and Neuromodulation for AD

Jürgen Götz, PhD *has nothing to disclose.*

FUS BBBO with a Portable FUS System and real time mapping

Elisa Konofagou, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Delsona - Ownership/Stock options

Forest Neurotech - Consultant/Advisory Board

Modulating Glial Activity with Focused Ultrasound against Alzheimer's disease

Sophie Morse, PhD *has nothing to disclose.*

Combination of focused ultrasound blood-brain barrier opening with Lecanemab therapy in mild Alzheimer's disease.

Ali R Rezai, MD *has nothing to disclose.*

Monday, July 28, 2025, AAIC Disclosures

8:00-8:45 am

2-2-FRS-D Novel in vivo models of neurodegeneration II

Traumatic brain injury derived pathological tau polymorphs induce the distinct propagation pattern and neuroinflammatory response

Nemil Bhatt, PhD *has nothing to disclose.*

NON-TOXIC TAU OLIGOMER POLYMORPH ISOLATED FROM NON-DEMENTED INDIVIDUALS WITH ALZHEIMER'S NEUROPATHOLOGY BRAINS

Anna Fracassi, PhD *has nothing to disclose.*

Unravelling the role of APOE4 in vascular dysfunction and cognitive impairment

Krystal K. Laing, MS *has nothing to disclose.*

2-3-DEV Developing Topics on Genetics

Interactive effects of telomere length, mtDNA abundance, and epigenetic age on Alzheimer's disease endophenotypes

Shea J Andrews, PhD *has nothing to disclose.*

Hormone replacement therapy in women and vascular risk factors modify the association of a multi-ancestry polygenic risk score with Alzheimer disease and related traits

Nuzulul Kurniansyah, MS *has nothing to disclose.*

Long-Read Sequencing Reveals Ancestral intragenic APOE Haplotypes with Distinct Roles in Alzheimer's Disease

Agustin Ruiz, MD, PhD *has nothing to disclose.*

Parental history of memory impairment predicts tau-PET accumulation in a preclinical population

Mabel Seto, PhD *has nothing to disclose.*

2-4-LPR Preclinical drug discovery: targetting amyloid

Protective Effects of Resveratrol Against Amyloid Beta-Induced Toxicity in Neuroblastoma Cells: Insights from Cell Viability and cellular energetics.

Manas Chakraborty, MS Pharmacy *has nothing to disclose.*

Profiling the immune response to anti-A β immunotherapy

Kate E. Foley, PhD *has nothing to disclose.*

Modulation of Amyloid-beta Metabolism by TIMP2 and MMP2 Through Extracellular Matrix Interactions in Mouse Models of Alzheimer's Pathology

Alejandro B. Grau-Perales, PhD *has nothing to disclose.*

Reduction of amyloid plaques and modulation of neuroinflammation in APP/PS1 mice at advanced stages of Alzheimer's disease by Plasma exchange with albumin replacement.

Suelyn Koerich, PhD *has nothing to disclose.*

Fabrication of Nose to Brain Delivery of Pterostilbene-Loaded Thermoresponsive Mucoadhesive Nanoemulgel to Mitigate Vascular Dementia

Vishal Shivaji Patil *has nothing to disclose.*

IK-5f targets amyloid aggregates and alleviates cognitive deficits in the 5XFAD Alzheimer mouse model

Heewon Shin *has nothing to disclose.*

Monday-037 Development of a novel anti-amyloid therapeutic: an orally administrable anti-abeta-oligomer compound in early preventative intervention

Hedi Zhou *has nothing to disclose.*

2-5-LPR Co-pathologies

PART characterization using MK-6240 and Flortaucipir

Carolina Soares, PhD *has nothing to disclose.*

Location patterns of white matter hyperintensities in a multi-cohort study — generalisability, evaluation, and longitudinal progression

Xin Zhao *has nothing to disclose.*

Monday-294 A β positive, tau biomarker negative cognitive impairment is associated with significant non-Alzheimer's disease neuropathologies

Konstantinos Ioannou, MD, MSc *has nothing to disclose.*

Monday-296 Systolic Blood Pressure and Type 2 Diabetes Modify the Relationship Between Alzheimer's Disease Biomarkers and Cognitive/Functional Impairment

Tamare V Adrien, MS *has nothing to disclose.*

Monday-401 Predicting cognitive decline in amyloid-negative individuals with amnesic mild cognitive impairment

Amanda Annettesdotter *has nothing to disclose.*

Monday-456 A probabilistic framework for the diagnostic utility of tau-PET

Bastiaan G J van Tol, MSc *has nothing to disclose.*

2-6-FRS-D Vascular contributions to cognitive impairment I

Does Cardiovascular Risk Mediate Associations Between Race/Ethnicity, Gender, and Neuroimaging Markers of Dementia? An Analysis from the HABS-HD Cohort

Michelle R. Caunca, MD, PhD *has nothing to disclose.*

The Intersection of Cognitive Function, Hypertension, and Social Determinants of Health: Insights from a Large, Multicenter Trial

Adam Parks, PhD *has nothing to disclose.*

Short sleep and nocturnal hypertension: A combined risk for neuronal damage

Stephanie Yiallourou, PhD *has nothing to disclose.*

2-7-FRS-D Neuropsychiatric symptoms and biomarkers II

Exploring the Cross-sectional Association of Mood Symptoms with Subjective and Objective Cognition in the A4 study

Idris Demirsoy, PhD *has nothing to disclose.*

Sex-specific effects of neuropsychiatric symptoms on amyloid and tau pathology and white matter hyperintensity volume in preclinical Alzheimer's disease

Aur lie Garrone, BSc *has nothing to disclose.*

The association of white-matter integrity with depression- symptoms among middle-aged adults at high risk for Alzheimer's disease and related disorders

Ramit Ravona-Springer, MD *has nothing to disclose.*

2-8-LPR Leveraging model systems to understand disease and therapeutic mechanisms

Studying APOE2 Protective Effects in Alzheimer's Disease Using Integrative Approaches and a Novel Mouse Model

Zherui Liang *has nothing to disclose.*

Monday-088 Single-cell transcriptomics analysis identifies oligodendrocyte-microglia crosstalk modulated by TREM2-R47H and exacerbated by APOE4 in Alzheimer's disease

Diana J Zajac, PhD *has nothing to disclose.*

Monday-110 Role of Alphaherpesviruses in Alzheimer's disease pathophysiology.

Axel Legrand, MSc *has nothing to disclose.*

Monday-151 Evaluating the Efficacy and Risks of Early Lecanemab Treatment in APOE4 Humanized Alzheimer's Disease Mouse Models

Arash Salahinejad, PhD *has nothing to disclose.*

Monday-156 Decoding the effects of Bexarotene treatment on brain of AD-like model mice: single-cell transcriptomics and chromatin accessibility analysis

Nicholas F Fitz, PhD *has nothing to disclose.*

Monday-173 APOE4 drives neuroinflammation and lipid dysbiosis in Alzheimer's disease by modulating lipid compositions and cell adhesion molecules in brain-derived extracellular vesicles

Zhengrong Zhang, PhD *has nothing to disclose.*

2-9-FRS-D Biomarker findings in global populations II

Validation of plasma p-tau217 as a Blood-Based Biomarker for dementia diagnosis in Latin American population

Ariel Caviedes, PhD *has nothing to disclose.*

The influence of demographic, genetic and neurodegenerative variations on biomarker profiles in a Southeast Asian community cohort

Jacklyn Leonardo *has nothing to disclose.*

Impact of social determinants of health on ATN biomarkers and neurodegeneration in the ReDLat cohort

Matias Pizarro, PhD student *has nothing to disclose.*

9:00-10:30 am

2-11-ECBS-C Crosstalk between oligodendrocytes, astrocytes and microglia

The next generation of spatial transcriptomics and AI to understand complex interactions between glial cells

Sudeshna Das, PhD *has nothing to disclose.*

Contributions of oligodendroglia to AD pathology

Shin Kang, PhD *has nothing to disclose.*

Understanding glia interaction with synapses

Beth Stevens, PhD *has nothing to disclose.*

Crosstalk between microglia and astrocytes

Eduardo R. Zimmer *has nothing to disclose.*

2-12-PER-C Understanding and interpreting clinical meaningfulness of trial data in AD

Patient/caregiver perspective -- outcomes that matter to people living with Alzheimer's Disease

Carla (DeMuro) Romano *has nothing to disclose.*

Conceptualizing meaningfulness for individuals versus groups

Cheryl Coon *has nothing to disclose.*

A clinical perspective on meaningful benefit

Ronald Petersen, MD, PhD *has nothing to disclose.*

Clinical relevance of disease-modifying therapies for Alzheimer's disease

Alette M. Wessels, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Eli Lilly and Company - Employee/Owner

2-13-FRS-A Preclinical advances in targeted brain delivery of large molecule therapeutics to treat Alzheimer's disease

Grabody B, an IGF1R-targeting Molecular Shuttle, Sustains Brain Penetration of Therapeutic Antibody in Aged Mice by Multiple, Novel Transcytosis Pathways

Sungwon An, PhD *has nothing to disclose.*

Computational analysis of delivery targets and trafficking at the blood-brain barrier: toward the design of brain-penetrant therapeutics for Alzheimer's disease

Habib Baghirov, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
AstraZeneca - Employee/Owner
Roche - Employee/Owner

The brain transcytosome: pooled in vivo screening of 1000s of biologics discovers novel "portal" receptors and mechanisms for macromolecule CNS delivery

Kimberly Searce-Levie, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Denali Therapeutics - Non-Mutual funds Stock

Manifold Bio - Employee/Owner

Brain transport platform for precision drug delivery of large molecule therapeutics to treat Alzheimer's disease

Liqun Wang, PhD *has nothing to disclose.*

Brain-targeted Nano-ERASER downregulates PD-L1 for Alzheimer's disease therapy

Peisheng Xu, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AcePre LLC - Employee/Owner

NanoPX Biosciences LLC - Employee/Owner

Utilizing the Brain Vasculature to Improve Delivery and Safety of the Next Generation of AD Therapeutics

Joy Zuchero, PhD *has nothing to disclose.*

2-14-FRS-C Endolysosomal dysfunction across neurodegenerative diseases

Heteromeric amyloid filaments of TDP-43 and annexin A11 in neurodegenerative diseases

Benjamin Falcon, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eli Lilly and Company - Speakers Bureau/Honoraria for non-CME

Fine-mapping of the TMEM106B locus reveals four haplotypes that are differentially associated with risk for neurodegeneration

Henne Holstege, PhD *has nothing to disclose.*

4R Tau Drives Endolysosomal Dysfunction in VCP-Related Frontotemporal Dementia

Christy Hung, PhD *has nothing to disclose.*

TDP-43 dysfunction and markers in Neurodegenerative Disease

Leonard Petrucelli, PhD *has nothing to disclose.*

2-15-FRS-C The World Health Organization's Global Action Plan on Dementia: Where Are We and Where Are We Headed?

Case Study: A Dementia Strategy for Canada: Together We Aspire

Franca Gatto *has nothing to disclose.*

From Plan to Impact

Dale Goldhawk *has nothing to disclose.*

Case Study: The U.S. National Alzheimer's Plan

Jennifer Pollack *has nothing to disclose.*

The WHO's Global Action Plan on Dementia

Katrin M. Seeher, PhD *has nothing to disclose.*

2-16-FRS-A culturally-sensitive neuropsychological evaluations

Drivers of Below-Cutoff Scores on Bedside Cognitive Screening in Cognitively Normal Ethnoracially Diverse Adults

Paula Aduen, PhD *has nothing to disclose.*

Fair Harmonization. How can we harmonize digital cognitive tools while also preserving local culture and context?

Karen Blackmon, PhD, ABPP-CN *has nothing to disclose.*

Identifying Alzheimer's Disease by combining plasma biomarkers and cross-cultural cognitive tests in an ethnically diverse mixed memory clinic cohort.

Daniel Kjaergaard *has nothing to disclose.*

Neuropsychological evaluation of cognitive decline in Latin America

Maira Okada de Oliveira, PhD *has nothing to disclose.*

Transcultural memory markers for Alzheimer's Disease: Evidence from the ReDLat project

Mario A A Parra, MD, PhD *has nothing to disclose.*

Cultural Effects of Demographic Factors on Cognitive Function: Findings from U.S. and Korea

Minji Song, PhD *has nothing to disclose.*

2-17-FRS-A Sex-specific risk and protective factors in Alzheimer's disease

No causal link between estradiol and Alzheimer's disease in females: a Mendelian randomization study.

Claudia Barth, PhD *has nothing to disclose.*

X Chromosome Genetic Risk Across Sex, APOE*4, and Pleiotropic Traits Reveals Novel Alzheimer's Disease Mechanisms and Risk Genes.

Noah Cook, MS *has nothing to disclose.*

Novel sex-specific candidate loci associated with Alzheimer disease identified through sex-aware multi-ancestry genome-wide meta-analysis

Brian W Kunkle, Ph.D. *has nothing to disclose.*

Sex and apolipoprotein E (APOE) genotype Interact to impact relationships among sleep, Alzheimer's disease biomarkers, and memory in older adults.

Negin Sattari, PhD *has nothing to disclose.*

Sex-stratified GWAS meta-analyses reveal novel sex-specific association with CSF biomarkers of Alzheimer's Disease

Ting-Chen Wang *has nothing to disclose.*

Genetic Pleiotropy Across Hormone-Related Traits and Alzheimer's Disease Reveals Sex-Specific Relationships and Risk Genes.

Chenyu Yang, MS *has nothing to disclose.*

2-18-FRS-A Longitudinal trajectories in preclinical AD and amyloid negative individuals

Elevated P-Tau217 is Strongly Associated with Longitudinal Neocortical Tau-PET in Younger Adults: Findings from the A4/LEARN studies and ADNI.

Gillian T Coughlan, PhD *has nothing to disclose.*

Longitudinal at-home assessment of connected speech acoustics in Dutch amyloid-positive cognitively normal adults

Casper de Boer, PhD *has nothing to disclose.*

Microglia-specific Alzheimer's disease polygenic risk score predicts longitudinal increase in plasma tau and faster cognitive decline in cognitively unimpaired older adults

Brahyan J Galindo Mendez, MD, MPH *has nothing to disclose.*

Vascular pathology drives the association of plasma GFAP with gray matter atrophy and cognitive decline in amyloid-negative individuals.

Matheus Scarpato Rodrigues, PhD *has nothing to disclose.*

Lifelong Determinants of Cognitive Ageing: Insights from the British 1946 Birth Cohort

Jonathan M Schott, MD FRCP *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eli Lilly - Consultant/Advisory Board

Roche - Consultant/Advisory Board

Longitudinal tau-PET accumulation and downstream effects in amyloid-beta negative cognitively unimpaired individuals

Anika Wuestefeld, M.Sc. *has nothing to disclose.*

11:00-12:15 pm

2-10-PL Plenary Session

Neurovascular interactions in Alzheimer's disease: From mechanisms to treatments

Katerina Akassoglou, PhD *has nothing to disclose.*

2-10-PL Plenary Session

The multiple facets of tau pathology

Maria Grazia Spillantini *has nothing to disclose.*

2:00-3:30 pm

2-19-FRS-C U.S. POINTER: Topline Results and Implications

U.S. POINTER: Topline Results of a Large Multisite Randomized Controlled Multidomain Lifestyle Intervention Trial

Laura D Baker, PhD *has nothing to disclose.*

U.S. POINTER: Design of the Multidomain Lifestyle Interventions

Jeff Katula, PhD *has nothing to disclose.*

U.S. POINTER Study: Adherence to a Multidomain Health Behavior Change Intervention

Jennifer Ventrelle, MS *has nothing to disclose.*

U.S. POINTER: Study Design, Recruitment, and Baseline Participant Characteristics of a Large Multisite Multidomain Lifestyle Intervention Trial

Rachel A. Whitmer, PhD *has nothing to disclose.*

2-20-FRS-A Preclinical Drug Discovery Targeting Neuroinflammation for Alzheimer's Disease and Related Dementias

Development of novel small molecule EPHB3 inhibitors to treat neurodegenerative disease by targeting astrocyte-mediated disease mechanisms

Evan P Lebois, PhD *has nothing to disclose.*

Decoding INPP5D/SHIP1: A Pivotal Regulator of Microglial Homeostasis in Alzheimer's Disease

Adrian L Oblak, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Monument Biosciences - Ownership/Stock options

A Novel TREM2 Small Molecule Agonist MTX46943 Re-Programs Human Microglia and Reduces Amyloid Pathology *In Vivo*

Manuela Polydoro, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Muna Therapeutics - Employee/Owner

Human specific divergent cytoskeletal evolution defines genetic background for innate immune function

Kinga Szigeti, MD, PhD *has nothing to disclose.*

Targeting Neuroinflammation by Bioreactive Nanoparticles for Early Detection and Intervention of Alzheimer's Disease

Liting Wang, PhD *has nothing to disclose.*

Proof of biology for amyloid plaque lowering therapies in pre-clinical models of Alzheimer's Disease

Choya Yoon, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Merck - Employee/Owner

2-21-FRS-A Remote collection of biomarkers for Alzheimer's disease and related disorders

The DROP-AD project: AD biomarkers from dry blood spots

Nicholas J. Ashton *has nothing to disclose.*

Effectiveness of Self-Administered Mobile Assessment in Detecting Mild Cognitive Impairment

Rhoda Au, PhD *has nothing to disclose.*

Pushing Boundaries with Remote Digital Cognitive Assessments in Alzheimer's Disease

Jason J. Hassenstab, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AlzPath - Consultant/Advisory Board

Prothena - Consultant/Advisory Board

Quanterix - Consultant/Advisory Board

SpeechDx: A gold-standard speech-and-language dataset for prognostic AD biomarker development

Lampros Kourtis, PhD *has nothing to disclose.*

Revolutionizing at-home testing of blood-based P-tau217 for early detection of Alzheimer's disease: A validation study of the Tasso Lancet Device

Elisabeth Thijssen, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Neurogen Biomarking - Employee/Owner

Vectory Therapeutics - Employee/Owner

Proteomics at our fingertips: Coupling remote collection devices with NULISA multiplex panels

Rachael E. Wilson, PhD *has nothing to disclose.*

2-22-FRS-A Drug Discovery Strategies and Enabling Methodologies

Miniaturization of Human iPSC-derived neuron long-term culture into high-throughput screening format for AD biology and therapeutics discovery

Yuhong Du, PhD *has nothing to disclose.*

Innovative Intranasal Nanocarriers of Butyrylcholinesterase and Kinase Inhibitors for Alzheimer's Disease: Immunohistochemistry, Biomarkers, Histopathology, and Antioxidant Perspective

SAIF AHMAD KHAN, M. Pharm *has nothing to disclose.*

Efferocytosis-Driven Reduction of Neuroinflammation and Amyloid Beta Burden via Novel GAS6 Fusion Protein, GAIA: A Promising Therapeutic Approach in Alzheimer's Disease

Jin Kyung Lee, PhD *has nothing to disclose.*

Combining xQTL and genome-wide association studies from ethnically diverse populations improves druggable gene discovery

Noah J Lorincz-Comi, PhD *has nothing to disclose.*

Discovery of an ApoE4-Targeted Small-Molecule SirT1 Enhancer for the Treatment of Alzheimer's Disease

Samar Padder, BS *has nothing to disclose.*

Systemic Delivery of ApoB¹¹-Conjugated Antisense Oligonucleotide Reduces α -Synuclein Aggregates and Improves Cognitive and Motor Function in a DLB Mouse Model

Robert A. Rissman, PhD *has nothing to disclose.*

2-23-FRS-A Understanding and Quantifying Tau Heterogeneity in Alzheimer's Disease

Individual functional connectivity constraints on spatial progression of tau pathology in Alzheimer's disease

Harry H Behjat, PhD *has nothing to disclose.*

Tau PET load in early- and late-onset Alzheimer's disease: A cross-sectional and longitudinal comparison of the LEADS and ADNI cohorts

Konstantinos Chiotis, MD, PhD *has nothing to disclose.*

Heterogeneous tau patterns in atypical AD are explained by connectivity-associated tau progression

Hannah de Bruin, MSc. *has nothing to disclose.*

Regional tau quantification methodologies in early symptomatic participants with presence of tau pathology

Diana O Svaldi, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eli Lilly and Company - Employee/Owner, Ownership/Stock options

White Matter Hyperintensities Correlate with Accelerated Tau Accumulation in Posterior Cortical Regions in Alzheimer's Disease

Jie Yang, M.Med *has nothing to disclose.*

Heterogeneity in tau onset, patterns and accumulation rates are explained by age of amyloid onset

Zeyu Zhu, MSc *has nothing to disclose.*

2-24-FRS-C Global Solutions for Dementia Prevention: The Role of Online Educational Programs, Coaching, and Interventional Trials

Protect AD: Realizing New Clinical Trial Possibilities

Clive G Ballard, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Abbvie - Consultant/Advisory Board

acadia - Consultant/Advisory Board

alkermes - Speakers Bureau/Honoraria for non-CME

BMS - Consultant/Advisory Board

e lilly - Consultant/Advisory Board

GSK - Consultant/Advisory Board

maplight - Consultant/Advisory Board

novo nordisk - Consultant/Advisory Board

roche - Consultant/Advisory Board

signant health -

TauRx - Consultant/Advisory Board

Brain Health PRO: Evaluating a Web-Based Multidomain Intervention to Improve Dementia Literacy and Self-Efficacy

Sylvie Belleville, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Innovatek International - Consultant/Advisory Board

Lucilab - Consultant/Advisory Board

Maintain Your Brain: recent findings, future challenges

Henry Brodaty, MD, DSc *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biogen - Consultant/Advisory Board

Cranbrook Care - Consultant/Advisory Board

Eisai - Consultant/Advisory Board

Eli Lilly - Consultant/Advisory Board

Medicines Australia - Consultant/Advisory Board

Roche - Consultant/Advisory Board

Skin2Neruo - Consultant/Advisory Board

A web-based multidomain intervention improves modifiable risk factors for Alzheimer's disease

Haakon B. Nygaard, MD, PhD *has nothing to disclose.*

2-25-FRS-A Insights from the measurement of intra-individual variability in cognitive performance

Cognitive variability in healthy and impaired older adults: What is it? What causes it? How to measure it?

Andrew J. Aschenbrenner, PhD *has nothing to disclose.*

Greater Cognitive Intraindividual Variability Predicts Faster Decline in Everyday Functioning: Moderating Effects of Amyloid Status and APOE Genotype

Katherine J. Bangen, PhD *has nothing to disclose.*

Early Cognitive Dispersion and Risk of Cognitive Impairment: Insights from the ELSA-Brasil Study

Laiss Bertola, PhD *has nothing to disclose.*

Developing and validating normed scores for cognitive dispersion among older adults

Andrew M. Kiselica, PhD *has nothing to disclose.*

Intraindividual standard deviation vs. Coefficient of variation: a comparative analysis of late-life cognitive dispersion

Truc Tran Thanh Nguyen, MD, MS *has nothing to disclose.*

Uncovering Unique Effects in Preclinical Alzheimer's Disease with Digital Cognition

Matthew S. Welhaf, PhD *has nothing to disclose.*

2-26-FRS-A Sex Differences and Sex-Specific Factors Contributing to Women's Increased Risk of Alzheimer's Disease

The sex divide: Modifiable risk factors and their relative associations with cognition

Megan Fitzhugh *has nothing to disclose.*

The parity paradox: Differential effects on functional connectivity depending on APOEε4 genotype in middle age

Bonnie H Lee, BSc *has nothing to disclose.*

Sex moderates the association between medial temporal tau pathology and cognitive decline: A multi-cohort study

Annie Li, BA *has nothing to disclose.*

Leveraging menopause to uncover novel insights into Alzheimer's disease pathophysiology

Rowan Saloner, PhD *has nothing to disclose.*

The combined influence of earlier menopause and cardiac function on brain health

Tallinn Splinter, BSc *has nothing to disclose.*

The interplay between synaptic integrity and age at menopause on Alzheimer's disease risk in women

Madeline Wood Alexander, BA *has nothing to disclose.*

2-27-FRS-A Insights into disease trajectory and biological staging of AD

A β -dependent trajectories of Braak stages for MK6240 and Flortaucipir tau PET

Bruna Bellaver *has nothing to disclose.*

Factors influencing tau trajectories along the amyloid timeline from three cohorts

Tobey J. Betthauser, PhD *has nothing to disclose.*

Characterizing amyloid and tau PET-based biological stages along the clinical continuum in NACC participants

Karly Cody, PhD *has nothing to disclose.*

Unveiling Factors Contributing to Cortical Tau Tangle Accumulation and Spread Beyond β -Amyloid in Alzheimer's Disease

Tengfei Guo, PhD *has nothing to disclose.*

Evaluation of the revised criteria for biological and clinical staging of Alzheimer's disease

Alexa Pichet Binette, PhD *has nothing to disclose.*

Biological staging of Alzheimer's disease with the novel plasma eMTBR-tau243 and %p-tau217

Gemma Salvadó, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Adium - Speakers Bureau/Honoraria for non-CME

Springer - Speakers Bureau/Honoraria for non-CME

3:30-4:15 pm

2-A-GEP Guided Electronic Poster Tour: Sex and gender influences on aging and AD continuum pathology: bridging genetic, hormonal, reproductive, and adversity-related factors

Late motherhood linked to accelerated memory decline in amyloid-positive cognitively unimpaired women

Anna Brugulat-Serrat, PhD *has nothing to disclose.*

Task fMRI recognition activation at midlife associated with gender-influenced chronic stressor exposure in women at risk of Alzheimer's disease

Xiaowei Zhuang, PhD *has nothing to disclose.*

Sunday-404 Sex Moderates Relationships Between P-Tau217 and Longitudinal Tau-PET: A Multi-Cohort Study

Gillian T Coughlan, PhD *has nothing to disclose.*

Sunday-405 Sex & menopause related differences in vascular health and rsfMRI connectivity in middle-aged adults

Julia Kearley, MS *has nothing to disclose.*

2-B-GEP Guided Electronic Poster Tour: Risk and Resilience in Genetically Deterministic Forms of Alzheimer's Disease

Sunday-015 Resilience to Alzheimer's disease in individuals with Down syndrome

Lisi Flores Aguilar, PhD *has nothing to disclose.*

Sunday-239 Mild premorbid intellectual impairment as a resilience factor in Down syndrome associated Alzheimer's disease

James Tyler Kennedy, PhD *has nothing to disclose.*

Sunday-382 Task fMRI activity in an Autosomal Dominant mutation carrier demonstrating extreme resilience

Brian A. Gordon, PhD *has nothing to disclose.*

Sunday-494 Phenotypic and neuropathological heterogeneity in autosomal dominant familial Alzheimer's disease, and implications for amyloid-immunotherapy

Natalie S Ryan, PhD MRCP *has nothing to disclose.*

Sunday-534 Cardiovascular Risk Composite and Time of Amyloid Accumulation and Cognitive Decline in Down Syndrome Alzheimer's Disease

Courtney Brothers *has nothing to disclose.*

4:15-5:45 pm

2-28-ECBS-C The role of tau in cerebrovascular disease

Tau in vascular remodeling and blood-brain barrier dysfunction in AD

Rachel E Bennett, PhD *has nothing to disclose.*

Tau transmission: A key driver of senescence in non-neuronal brain cells

Veronica Galvan, PhD *has nothing to disclose.*

Cis P-tau underlies vascular contribution to cognitive impairment and dementia

Kun Ping Lu *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Pinteon Therapeutics - Ownership/Stock options

Tanycyte-mediated brain-to-blood efflux of tau is disrupted in AD

Florent Sauvé, PhD *has nothing to disclose.*

2-29-FRS-A Neuroinflammation, Microglia, Astrocyte and therapeutic strategies

Evidence for protective and deleterious microglial phenotypes in an individual underscores microglia as an attractive therapeutic target

Paul Edison, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Avid Radiopharmaceuticals - Grant/Research Support

Eli Lilly - Grant/Research Support

GE Healthcare - Grant/Research Support

Novo Nordic - Consultant/Advisory Board

Pfizer - Consultant/Advisory Board

Primal Life Science/Life Molecular Imaging - Grant/Research Support

Roche - Consultant/Advisory Board

Astrocyte reactivity and neurodegeneration biomarkers in critical care patients and strategies for intervention

Débora Guerini de Souza, PhD *has nothing to disclose.*

ASC speck mediated beta-amyloid seeding in Alzheimer's disease

Michael T. Heneka, Prof. Dr. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alector Inc - Consultant/Advisory Board

Muna Therapeutics - Consultant/Advisory Board

Astrocyte and Glial interaction in developing novel therapeutic strategies

Seyyed Ali Hosseini, MSc *has nothing to disclose.*

Inflammation clinical trial in mild to moderate Alzheimer's disease: TSPO-PET results

Belen Pascual, PhD *has nothing to disclose.*

Assessing reactive astrogliosis in aging and across the Alzheimer's disease spectrum with SMBT-1

Victor L Villemagne, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AC Immune - Speakers Bureau/Honoraria for non-CME

ACE Barcelona - Speakers Bureau/Honoraria for non-CME
Life Molecular Imaging - Consultant/Advisory Board

2-30-FRS-B Real-world clinical performance of blood biomarkers for the diagnosis of Alzheimer's Disease.

Performance of the Lumipulse plasma p-tau217 assay to assess eligibility for amyloid-lowering therapies

Alicia Algeciras-Schimmich, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Fujirebio Diagnostics - Consultant/Advisory Board

Roche Diagnostics - Consultant/Advisory Board, Speakers Bureau/Honoraria for non-CME

Plasma p-Tau217 assay performance in Japan: from preclinical/prodromal cohort to DMT registry.

Takeshi Iwatsubo, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai - Speakers Bureau/Honoraria for non-CME

Eli Lilly - Speakers Bureau/Honoraria for non-CME

Global multi-specialty clinician perspectives on the implementation of Alzheimer's disease blood biomarkers

Ashvini Keshavan, MRCP PhD *has nothing to disclose.*

Clinical performance of blood biomarkers across settings and countries

Sebastian Palmqvist, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

BioArctic - Consultant/Advisory Board

Eisai - Speakers Bureau/Honoraria for non-CME

Eli Lilly - Consultant/Advisory Board

Novo Nordisk - Consultant/Advisory Board

Roche - Speakers Bureau/Honoraria for non-CME

Determining eligibility for anti-amyloid treatments using blood biomarkers

Suzanne E. Schindler, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai - Consultant/Advisory Board

Eli Lilly - Consultant/Advisory Board

Novo Nordisk - Consultant/Advisory Board

2-31-PER-A Translating drug targets from validation towards clinical candidates within academia

Drug discovery pipeline in Brazil

Sergio T. Ferreira, PhD *has nothing to disclose.*

A collaboration framework to translate academic research to drug development

Fiona E Jeganathan, PhD *has nothing to disclose.*

Overcoming the barriers to drug discovery

Allan I. Levey, MD, PhD *has nothing to disclose.*

Novel Drug Target Enablement, what it takes to move from target to drug discovery program

Alan D. Palkowitz, PhD *has nothing to disclose.*

Progressing academic research towards drug development

Jim Ray *has nothing to disclose.*

The Neurolipid Atlas

Rik van der Kant, PhD *has nothing to disclose.*

2-32-FRS-A Characterizing sources of heterogeneity within biomarkers

Patient-level predicting AD onset using lifespan volumetric trajectories

Vladimir S Fonov, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

NeuroRX - Consultant/Advisory Board

Medial temporal lobe Tau-Neurodegeneration *mismatch* from MRI and plasma biomarkers identifies vulnerable and resilient phenotypes with AD

Xueying Lyu *has nothing to disclose.*

Personalized AI Models for Accelerated Aging

Sebastian Moguilner, PhD *has nothing to disclose.*

Dominant Trajectories of Aging-related Brain Atrophy Identified in 48,949 Individuals via a coupled Cross-sectional and Longitudinal Non-negative Matrix Factorization.

Ioanna Skampardoni *has nothing to disclose.*

Contribution of genetic and lifestyle factors in resistance- and resilience-related variability in longitudinal pathologic and neurodegeneration trajectory in Dominantly Inherited Alzheimer's Disease

Hye Joo Son, M.D, Ph.D. *has nothing to disclose.*

Disease timeline modelling of amyloid and tau PET reveals dynamic timescales of amyloid and tau accumulation in Alzheimer's disease

Alexandra L Young, PhD *has nothing to disclose.*

2-33-FRS-A Innovations and Interventions in Dementia Care Across Global Contexts

Using co-designed films to reduce burden and improve mood among Indian family carers: Results from a pilot randomized clinical trial

Bianca Brijnath, PhD *has nothing to disclose.*

A Culturally Tailored Dementia Training Model for Primary Healthcare Workers in Sub-Saharan Africa

David Brodie-Mends, MD *has nothing to disclose.*

Feasibility and Acceptability of iGeriCare: A Pilot Randomized Controlled Trial of Web-Based Dementia Education for Care Partners

Anthony J. Levinson, MA, MSc, MD *has nothing to disclose.*

Nonpharmacological interventions for the management of visuospatial disturbances in dementia in UK & Japan

Maki Suzuki, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Otsuka Pharmaceutical Co., Ltd. -

2-34-FRS-A Sensory Abnormalities in Dementia

Olfactory Impairment in Persons Living with Dementia

Alex Bahar-Fuchs, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

NewDays.ai - Consultant/Advisory Board

Non-verbal dichotic listening: a new, cross-cultural central hearing test for dementia

Chris JD Hardy, PhD *has nothing to disclose.*

Autonomic and neurosensory disorders in mild cognitive impairment and dementia with Lewy bodies subjects: characteristics, follow-up and neural basis

Morgane Linard, MD, PhD *has nothing to disclose.*

Practical Approaches to Identifying & Addressing Hearing Loss among Persons Living with Dementia

Carrie L Nieman, MD, MPH *has nothing to disclose.*

Associations between isolated and combined olfactory dysfunction and cognitive impairment with future dementia in community-dwelling older adults

Javier Oltra, PhD *has nothing to disclose.*

Sex differences in the relationship between hearing status and cognitive performance in individuals with mild cognitive impairment

Natalie A. Phillips, PhD *has nothing to disclose.*

2-35-FRS-A Sex and Gender differences in Frontotemporal Degeneration

Sex differences in the clinical manifestation of autosomal dominant frontotemporal dementia

Kaitlin B Casaletto, PhD *has nothing to disclose.*

Sex and Biomarkers in FTD

Sterre C.M. de Boer, MD PhD *has nothing to disclose.*

Behavioral and executive reserve as measured with MRI in women with autosomal dominant FTD

Jesús Garcia Castro, MD *has nothing to disclose.*

Sex differences in clinical phenotypes of behavioral variant frontotemporal dementia

Xulin Liu, PhD *has nothing to disclose.*

Overview of Sex and Gender in FTD

Carmela Tartaglia, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

EISAI - Consultant/Advisory Board

Lilly - Consultant/Advisory Board

Novo Nordisk - Consultant/Advisory Board

Female Informants are associated with higher CDR PLUS NACC-FTLD scores in patients with Frontotemporal Dementia.

Juan-Camilo Vargas-González, Ph.D., MSc, M.D. *has nothing to disclose.*

2-36-FRS-B Timing Alzheimer's Disease Progression: Biomarker Clocks and Beyond

Whole-brain functional connectivity predicts regional tau PET and future cognitive decline in preclinical Alzheimer's disease

Hamid Abuwarda *has nothing to disclose.*

Trajectories of CSF and plasma MTBR-tau 243 and phosphorylated-tau species across the Alzheimer's disease continuum

Lyduine E. Collij, PhD *has nothing to disclose.*

Using Proteomics to Stage Alzheimer's Disease

Erik C.B. Johnson, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eli Lilly - Consultant/Advisory Board

Predicting onset of Alzheimer disease symptoms with a plasma %p-tau217 clock

Kellen K. Petersen, PhD *has nothing to disclose.*

Untangling the multiple timescales of Alzheimer's disease

Lars Lau Raket, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Eli Lilly and Company - Employee/Owner

Tuesday, July 29, 2025, AAIC Disclosures

8:00-8:45 am

3-2-LPR Novel approaches in neuropathology of Alzheimer's disease and related dementia

Tuesday-110 Impaired A β Clearance Mechanisms at the Inner Blood-Retina Barrier in Alzheimer's Disease: Insights from Ex Vivo Retinal Imaging.

Printha Wijesinghe, PhD *has nothing to disclose.*

Tuesday-112 Associations between co-pathology and diagnostic concordance in neurodegeneration: post-mortem analysis of the Amsterdam dementia cohort

Willem L. Hartog, MD *has nothing to disclose.*

Tuesday-115 Unraveling the Heterogeneity of Dementia Progression in Alzheimer's Disease and the Impact of Lewy Body Co-Pathology

MOHAMMED WASEEQUR RAHMAN, MSc *has nothing to disclose.*

Tuesday-116 Mass spectrometry imaging of Alzheimer's disease vulnerable and resilient neocortical areas in postmortem formalin-fixed paraffin-embedded and fresh frozen human brains

Tassia Venga Mendes, PhD *has nothing to disclose.*

Tuesday-126 Circadian-regulating nuclei in the human anterior hypothalamus demonstrate selective vulnerability to pathological effects of Alzheimer's disease

Grace Judge *has nothing to disclose.*

Tuesday-598 Women with Down syndrome show more severe Alzheimer's disease neuropathology with regional differences

Elizabeth J. Andrews, BSc *has nothing to disclose.*

3-3-CTB-B Donanemab: Appropriate Use Recommendations and Clinical Implementation

Panelist

Jeffrey L. Cummings, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

o Acadia, Acumen, ALZpath, Annovis, Aprinoia, Artery, Axsome Therapeutics, Biogen, Biohaven, BioXcel, Bristol-Myers Squib, Eisai, Fosun, GAP Foundation, Green Valley, Janssen, Karuna, Kinaxis, Lighthouse, Lilly, Lundbeck, LSP/eqt, Merck, MoCA Cognition, N -

Consultant/Advisory Board

US National Institute of General Medical Sciences (NIGMS) grant P20GM109025, National Institute on Aging (NIA) grant R35AG71476, NIA grant R25 AG083721-01, the Alzheimer's

Disease Drug Discovery Foundation (ADDF), the Ted and Maria Quirk Endowment, and th -
Grant/Research Support

Panelist

Ronald Petersen, MD, PhD *has nothing to disclose.*

Donanemab Appropriate Use Recommendations

Gil D. Rabinovici, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

C2N - Consultant/Advisory Board

Eli Lilly - Consultant/Advisory Board

Panelist

Stephen Salloway, MD *has nothing to disclose.*

Panelist

Sharon J Sha, MD, MS *has nothing to disclose.*

3-4-FRS-D Early Phase Studies Exploring Diverse Mechanisms I

Multiple-Dose Results from an Ongoing Phase 1 Study of Mivelsiran, an Investigational RNA Interference Therapeutic Targeting Amyloid-Beta Precursor Protein for Alzheimer's Disease

Sharon Cohen *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AbbVie - Grant/Research Support

AgeneBio - Grant/Research Support

Alector - Grant/Research Support

Alnylam - Grant/Research Support, Consultant/Advisory Board

Alzheon - Grant/Research Support

Anavex - Grant/Research Support

Biogen - Grant/Research Support, Consultant/Advisory Board

Biohaven - Consultant/Advisory Board

BMS - Grant/Research Support, Consultant/Advisory Board

Cassava - Grant/Research Support, Consultant/Advisory Board

Cognivue - Consultant/Advisory Board

CogState - Consultant/Advisory Board

Davos Alzheimer's Collaborative - Grant/Research Support

Eisai - Grant/Research Support, Consultant/Advisory Board

Eli Lilly - Grant/Research Support, Consultant/Advisory Board

Global Alzheimer's Platform Foundation - Grant/Research Support

GSK - Grant/Research Support, Consultant/Advisory Board

INmune Bio - Grant/Research Support, Consultant/Advisory Board

Janssen - Grant/Research Support

Kisbee Therapeutics - Consultant/Advisory Board

Lundbeck - Consultant/Advisory Board

Novartis - Consultant/Advisory Board

Novo Nordisk - Grant/Research Support, Consultant/Advisory Board

Parexel - Consultant/Advisory Board

RetiSpec - Grant/Research Support, Consultant/Advisory Board

Roche - Grant/Research Support, Consultant/Advisory Board
SciNeuro Pharmaceuticals - Consultant/Advisory Board
UCB Biopharma - Grant/Research Support

Baseline Characteristics and Results of the Phase 2 COG1201 SHIMMER Study of Zervimesine (CT1812)

James E. Galvin, MD, MPH *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alpha Cognition - Consultant/Advisory Board
Biogen - Consultant/Advisory Board
Bristol Meyers Squibb - Consultant/Advisory Board
CervoMed - Grant/Research Support
CND Life Sciences - Grant/Research Support
Cognition Therapeutics - Grant/Research Support
Cognivue, Inc - Employee/Owner
DiagnaMed - Consultant/Advisory Board
Eisai - Consultant/Advisory Board
Eli Lilly - Consultant/Advisory Board
GE Healthcare - Consultant/Advisory Board
Lundbeck - Consultant/Advisory Board
Roche - Consultant/Advisory Board

Chemical-Driven Clearance of A β and tau Aggregates by Orally Available Small Molecule Drug Candidate AS-S603

YoungSoo Kim, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Amyloid Solution Inc. - Ownership/Stock options

3-5-LPR Non-AD cognitive impairment

The role of premorbid and psychosocial factors in the cognitive assessment of persons with and without HIV in a low-income area in South Africa

Anna Jane Dreyer, PhD *has nothing to disclose.*

Cognitive heterogeneity of data-driven phenotypes and associations with ADRD and cerebrovascular biomarkers in the Atherosclerosis Risk in Communities Study

Alexandra J. Weigand, MS *has nothing to disclose.*

Tuesday-548 Antioxidant N-acetylcysteine as an intervention for neuropsychiatric symptoms in individuals with vascular mild cognitive impairment

Alan (Jing Chiuan) Peng *has nothing to disclose.*

Tuesday-561 Cerebellar degeneration and its integrative role in brain networks for social cognition in early-stage bvFTD

Yu Chen, MD, PhD *has nothing to disclose.*

Tuesday-783 Cognitive Trajectories in Parkinson's Disease and Lewy Body Disease

Julia W. Gallini, MSPH *has nothing to disclose.*

3-6-LPR Risk factors for dementia in underrepresented populations

Alzheimer's disease and related dementias among transfeminine adults: A cohort study

Ethan C. Cicero, PhD, RN, FAAN *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alzheimer's Association - Grant/Research Support

NIH - Grant/Research Support

World Professional Association for Transgender Health - Speakers Bureau/Honoraria for non-CME

Alzheimer's Disease and Related Dementia and Related Health Conditions Among American Indian and Alaska Native Medicare Beneficiaries

Luohua Jiang, MD, PhD *has nothing to disclose.*

Implementing Culturally Informed Dementia Risk Reduction Strategies in First Nations Communities: A Continuous Quality Improvement Approach

Sarah G Russell, PhD *has nothing to disclose.*

Integrating Contextual Determinants and Polygenic Risk to Examine Dementia and Cognition in the Multi-Ethnic Study of Atherosclerosis

Diane Xue, PhD *has nothing to disclose.*

Dementia Risk factors Disparities and Population-Attributable Fraction in Ethiopia

Muluken Azage Yenesew, PhD *has nothing to disclose.*

Tuesday-766 Incidence and Prevalence of Dementia among Ontario Adults with and without Intellectual and Developmental Disabilities

Prachi Patel *has nothing to disclose.*

3-7-FRS-D Exploring Cognitive and Psychosocial Determinants of Dementia Outcomes I

Mental health, biological aging, and lifestyle mediate the associations between social determinants of health and dementia

Pei-Yang Gao, MD, PhD *has nothing to disclose.*

Evaluating the Impact of Alcohol on Dementia: Evidence from 13 Developing Countries

Cyprian M Mostert, PhD *has nothing to disclose.*

The moderating effect of cognitive function on the relationship between depression and behavioral activation in older adults

Yeonjoo Nam, MD *has nothing to disclose.*

3-8-LPR Neuroimaging insights into clinical manifestations

Voxel-wise longitudinal changes between amyloid PET and executive function subcomponents at the preclinical stage of the Alzheimer's continuum

Oriol Grau-Rivera, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

F. Hoffmann-La Roche Ltd - Grant/Research Support

Diagnostic performance of MK and Flortaucipir tau PET for the biological staging of Alzheimer disease

Marina Scop Madeiros, MD *has nothing to disclose.*

Genetic and Pathological Characteristics of Frontotemporal Dementia with Right Anterior Temporal Predominance: A Multicenter Retrospective Cohort Study

Hulya Ulugut, MD, PhD *has nothing to disclose.*

Clinical and cognitive manifestations of hemispheric asymmetry in neuroimaging biomarkers in early onset AD

Jacob Ziontz, PhD *has nothing to disclose.*

Tuesday-504 Different Patterns of Propagation of Tau Tangle Pathology in Typical Alzheimer's Disease Determine Clinical Sub-Phenotypes

Rayan Mroué, MD *has nothing to disclose.*

Tuesday-541 Interplay of Hypoperfusion and Neuroinflammation: Effects on Biomarkers and Cognition in Mild Cognitive Impairment

Jia Dong James Wang *has nothing to disclose.*

3-9-LPR Blood based biomarkers in clinical practice

Plasma Phosphorylated Tau 217 predicts cognitive and functional deterioration across clinical stages of Alzheimer's disease

Judit Selma-Gonzalez, MSc *has nothing to disclose.*

A Prospective Evaluation of Real-World Experience with an Alzheimer's Blood-Based Biomarker Panel in Memory Clinics: The CANTATE Project

Sinthujah Vigneswaran, MD *has nothing to disclose.*

Tuesday-227 Reference proteins to improve performance of core 1 and core 2 Alzheimer's disease CSF and plasma biomarkers

Linda Karlsson *has nothing to disclose.*

Tuesday-337 A protein panel including pTau217 outperforms pTau217 alone in identifying high tau load in amyloid positive individuals.

Guglielmo Di Molfetta, MSc *has nothing to disclose.*

Tuesday-352 Combining p-tau217 with Other Blood Biomarkers to Enhance Prediction of Cognitive Decline: A Large Memory Clinic Cohort Study

Monika Renuka Sanotra, PhD *has nothing to disclose.*

Tuesday-440 Plasma biomarkers of neuroinflammation and neurodegeneration in relation to cerebral glucose hypometabolism in autosomal-dominant Alzheimer's disease

Catarina Tristão-Pereira, PhD *has nothing to disclose.*

9:00-10:30 am

3-11-ECBS-C Impact of medical comorbidities on accumulation of ADRD neuropathology and biomarker readouts

Extent and clinical effects of AD comorbidities in longitudinal clinicopathological studies

Thomas G Beach *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Aprinolia Therapeutics - Consultant/Advisory Board

Biogen - Consultant/Advisory Board

Impact of blood-brain barrier integrity on plasma AD biomarkers

Bruna Bellaver *has nothing to disclose.*

Pathogenic Interplay of Alpha-Synuclein, Tau, and Amyloid Beta in Lewy Body Dementia

Pamela J. McLean, PhD *has nothing to disclose.*

Impact of comorbidities on biomarkers of Alzheimer's disease and related dementias

Michelle M Mielke, Ph.D. *has nothing to disclose.*

3-12-DEV Alzheimer's Disease and Related Dementias (ADRD) Clinical Trials Early Career Investigator Oral Abstracts Session

Streamlining Recruitment for AD Clinical Trials: Concurrent Detection of Cognitive Impairment and Amyloid-Beta PET Status with a Machine Learning-Enabled Digital Cognitive Assessment

Ali Jannati, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Linus Health - Employee/Owner, Ownership/Stock options

HEARS-NPS: A Randomized-Controlled Trial of Community-Delivered Hearing Care for Persons with Alzheimer's disease and Related Dementias (ADRD) and their Care Partners

Carrie L Nieman, MD, MPH *has nothing to disclose.*

Safety and Efficacy of Concomitant Intensive Systolic Blood Pressure Control with Anti-amyloid Monoclonal Antibodies in Reducing Amyloid Related Imaging Abnormalities

Jeremy J. Pruzin, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai - Consultant/Advisory Board

Synapticure - Employee/Owner

Outcomes of Community Input on Research Recruitment at an Alzheimer's Disease Research Center

Antoine R Trammell, MD, MPH *has nothing to disclose.*

Phase 1b/2a, 6-month, randomized, double-blind, placebo-controlled study of the safety/tolerability and preliminary evidence of efficacy of a tau-targeted therapeutic in patients with corticobasal syndrome.

Lawren VandeVrede, MD/PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Lilly - Speakers Bureau/Honoraria for non-CME

Roche - Consultant/Advisory Board

3-13-PER-C Potential targets for AD treatment

Sex Hormone Therapies and Alzheimer's Disease: Prevention vs Treatment

Roberta Diaz Brinton, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

NeuTherapeutics - Employee/Owner

Lithium role in attenuating AD pathology

Orestes Vicente Forlenza, MD, PhD *has nothing to disclose.*

Galectin-1 as a therapeutic strategy and a biomarker for Alzheimer's disease

Flavia Saravia, PhD *has nothing to disclose.*

Discovery of small molecule candidate therapeutics against neuroimmune targets in Alzheimer's disease

Linda Jo Van Eldik, PhD *has nothing to disclose.*

3-14-DEV Alzheimer's Disease Heterogeneity

The higher benefit of lecanemab in males compared to females in CLARITY AD is probably due to a real sex effect

Daniel Andrews *has nothing to disclose.*

Performance of plasma p-tau217 and NfL in an unselected memory clinic setting

Thomas Claessen, MD *has nothing to disclose.*

The Double-Edged Sword of Perseverance: Active Coping, Grit, and Cognitive Health in Black American Men

Darlingtona Esiaka, PhD *has nothing to disclose.*

Anti-amyloid treatments: Why we think they are worth it

Suzanne E. Schindler, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai - Consultant/Advisory Board

Eli Lilly - Consultant/Advisory Board

Novo Nordisk - Consultant/Advisory Board

3-15-FRS-A Social determinants of health: major players of cognitive health and dementia

Social Determinants of Health as Predictors of Accelerated Alzheimer's Disease Biomarker Accumulation and Cognitive Deterioration

Hanna Cho, MD, PhD *has nothing to disclose.*

Risk factors associated with neurocognitive disorder and depression among adults from an urban-marginalized area of Lima, Peru

Monica M Diaz, MD, MS *has nothing to disclose.*

Neighborhood Poverty Exposure in Adulthood and Cognitive Outcomes in Later Life.

Lucie Kalousova, PhD *has nothing to disclose.*

Understanding Social Determinants of Health and Cognitive Impairment Risk in Diverse Populations Using Machine Learning: A HABS-HD Study

Ibshar Khandakar, MPH *has nothing to disclose.*

EMERGING RISK FACTORS FOR COGNITIVE DYSFUNCTION AMONG 1036 COMMUNITY-DWELLING OLDER NIGERIAN AFRICANS: DATA FROM THE VALIANT STUDY

Oladotun V Olalusi, MD *has nothing to disclose.*

Effects of Apolipoprotein E Genotype and Education on Cognitive Function

Shan Wei, MD *has nothing to disclose.*

3-16-FRS-A Speech and language methods for the detection and tracking of cognitive decline

An objective and sensitive electrophysiological marker of word semantic categorization impairment in Alzheimer's disease

Justine David *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Bioserenity - Employee/Owner

Gauging speech and language markers of dementia against pathological and neuroimaging data.

Adolfo M. Garcia, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

TELL Toolkit SA - Ownership/Stock options

Associations Between Self-reported History of Traumatic Brain Injury on Longitudinal Cognitive and Speech Changes Linked to Alzheimer's Disease Risk Factors

Deling He, PhD *has nothing to disclose.*

Leveraging Digital Speech Features for Early Identification of Alzheimer's Disease: Associations with structural and functional brain changes over time

Qingyue Li *has nothing to disclose.*

Relationship Between the Digital Assessment of Cognition and Paper and Pencil Neuropsychological Tests

David J. Libon, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Linus Health - Consultant/Advisory Board

Mini-Linguistic State Examination (MLSE): Preliminary Normative Data for the French-Canadian Version of an International Screening Tool for Primary Progressive Aphasia

Elizabeth Poulin *has nothing to disclose.*

Automated Lexical Dysfluency Analysis to Differentiate Primary Progressive Aphasia Variants

Jet MJ Vonk, PhD, PhD *has nothing to disclose.*

3-17-FRS-C What is Atypical for AD? From Syndrome to Biology

Sleep Disruption in Early-Onset Alzheimer's Disease

Neus Falgàs Martínez, MD, PhD *has nothing to disclose.*

Cellular Vulnerability and Concomitant Pathology in Atypical AD

Lea T. Grinberg, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Guidepoint Inc - Consultant/Advisory Board

Otsuka -

Roche - Grant/Research Support

Imaging Heterogeneity in Atypical AD

Rosaleena Mohanty, PhD *has nothing to disclose.*

Memory impairment across the atypical AD syndromic spectrum

Deepti Putcha, PhD *has nothing to disclose.*

3-18-FRS-C Tunneling nanotubes: connecting immunity and neurodegeneration

Patient-derived iPS cells to study TNT-mediated interaction between microglia and neurons

Dimitri Budinger *has nothing to disclose.*

Neurodegenerative Disease Spread via the Tunneling Nanotubes

Sunayana Dagar, PhD *has nothing to disclose.*

Mitochondrial transfer and dynamics configures neural physiology through intercellular communications.

Rubén Quintana-Cabrera *has nothing to disclose.*

Tunneling nanotubes in microglia-synapse crosstalk and inflammation

Colleen R Zaccard, PhD *has nothing to disclose.*

11:00-12:15 pm

3-10-PL Plenary Session

Alzheimer's disease in Down syndrome

Juan Fortea, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AC Immune - Consultant/Advisory Board

Adamed - Speakers Bureau/Honoraria for non-CME

Admirall - Speakers Bureau/Honoraria for non-CME

Biogen - Speakers Bureau/Honoraria for non-CME

Eisai - Consultant/Advisory Board

Esteve - Speakers Bureau/Honoraria for non-CME

Ionis - Consultant/Advisory Board

Life Molecular Imaging - Grant/Research Support

Lilly - Consultant/Advisory Board

Perha - Consultant/Advisory Board

Roche - Consultant/Advisory Board

Zambon - Consultant/Advisory Board

3-10-PL Plenary Session

The Gut-Brain Axis in Alzheimer's Disease: Unraveling Pathogenesis and Exploring Novel Therapeutic Strategies

Inhee Mook-Jung, PhD *has nothing to disclose.*

2:00-3:30 pm

3-19-FRS-A New iPSC tools to study neuroimmune interactions in Alzheimer's disease

A human iPSC model of Tauopathies engineered for 4R Tau isoform expression endogenously develops late-stage neuronal Tau pathology

Angelika Dannert, PhD *has nothing to disclose.*

Novel regulators of nucleic acid sensing drive neurotoxic interferon response in microglia

Amanda McQuade, PhD *has nothing to disclose.*

iPSC villages to understand neuroimmune changes in Alzheimer's disease

Martine Therrien, PhD *has nothing to disclose.*

Hyperexcitable Circuits in the Etiology of Psychosis in Alzheimer's Disease.

Matheus B Victor, PhD *has nothing to disclose.*

Multispectral organelle imaging to model differentiation and neurodegeneration

Maria Clara Zanellati *has nothing to disclose.*

3-20-FRS-A Integrative neuropathology studies in Alzheimer's disease and related dementia

Tau vulnerability in entorhinal substructure and tau's proximity to vasculature

Jean Augustinack, PhD *has nothing to disclose.*

Superficial Cortical A β Clearance and ARIA Pathology in Aducanumab-Treated Alzheimer's Disease

Baayla D.C. Boon, MD, PhD *has nothing to disclose.*

A vascular component to the selective vulnerability of the medial temporal lobe in Alzheimer's disease

Vincent Doyon, MSc *has nothing to disclose.*

Insulin Resistance in Human Hippocampal Pyramidal Neurons Correlates with Age in Cognitively Normal and Alzheimer's Disease Patients

Xuelin Gu *has nothing to disclose.*

Neuronal transcriptional changes associated with incipient Alzheimer's disease neuropathology in entorhinal cortex

Jean-Pierre Roussarie, PhD *has nothing to disclose.*

The Alzheimer's Cell Atlas: A comprehensive brain single-cell transcriptomic atlas using a generative AI foundation model

Jielin Xu, PhD *has nothing to disclose.*

3-21-DEV Evidence-Based Clinical Practice Guidelines for Detection and Diagnosis of Cognitive Impairment using Blood-based Biomarkers and Cognitive Testing: Two Guideline Initiatives from the Alzheimer's Association

Clinical practice guideline for blood-based biomarkers in the diagnostic workup of Alzheimer's disease within specialized care settings: A report from the Alzheimer's Association

Sebastian Palmqvist, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

BioArctic - Consultant/Advisory Board

Eisai - Speakers Bureau/Honoraria for non-CME

Eli Lilly - Consultant/Advisory Board

Novo Nordisk - Consultant/Advisory Board

Roche - Speakers Bureau/Honoraria for non-CME

Clinical Practice Guideline on Cognitive Assessments for the Early Detection of Cognitive Impairment in Primary Care: A report from the Alzheimer's Association

Malavika Tampi, MPH *has nothing to disclose.*

3-22-DEV Developing Topics on Clinical Trials and Cohorts

Association Between Vascular Risk Factors and White Matter Integrity Among Diverse Middle-Aged and Older Hispanic/Latino Adults from the SOL-INCA-MRI study

Elmira Agah, MD *has nothing to disclose.*

Evaluating the Feasibility of a Personalized Endpoint in Down Syndrome-associated Alzheimer's Disease: Inventory-facilitated Goal Attainment Scaling

Chere Chapman, MBA, MHSc *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Ardea Outcomes - Employee/Owner

MINDFuL: a Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2 Clinical Trial of XPro1595 for Patients with Early Alzheimer's Disease and Biomarkers of Inflammation

Sharon Cohen *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AbbVie - Grant/Research Support

AgeneBio - Grant/Research Support

Alector - Grant/Research Support

Alnylam - Consultant/Advisory Board, Grant/Research Support

Alzheon - Grant/Research Support

Anavex - Grant/Research Support

Biogen - Consultant/Advisory Board, Grant/Research Support

Biohaven - Consultant/Advisory Board

BMS - Grant/Research Support

Bristol-Myers Squibb - Consultant/Advisory Board

Cassava Sciences - Consultant/Advisory Board, Grant/Research Support
Cognivue - Consultant/Advisory Board
Cogstate - Consultant/Advisory Board
Conference Board of Canada - Consultant/Advisory Board
Davos Alzheimer's Collaborative - Consultant/Advisory Board
Eisai - Consultant/Advisory Board, Grant/Research Support
Eli Lilly - Consultant/Advisory Board, Grant/Research Support
GAP - Grant/Research Support
GlaxoSmithKline - Consultant/Advisory Board, Grant/Research Support
INmuneBio - Consultant/Advisory Board, Grant/Research Support
Janssen - Grant/Research Support
Kisbee Therapeutics - Consultant/Advisory Board
Lundbeck - Consultant/Advisory Board
Novartis - Consultant/Advisory Board
Novo Nordisk - Consultant/Advisory Board, Grant/Research Support
Parexel - Consultant/Advisory Board
RetiSpec - Consultant/Advisory Board, Grant/Research Support
Roche - Consultant/Advisory Board, Grant/Research Support
SciNeuro Pharmaceuticals - Consultant/Advisory Board
UCB Biopharma - Grant/Research Support

Amyloid-accumulating cortical regions show selectively greater longitudinal thinning in the presence of ARIA during anti-amyloid therapy

Sandhitsu R Das *has nothing to disclose.*

Antiviral therapy: Valacyclovir Treatment of Alzheimer's Disease (VALAD) Clinical Trial

Davangere P. Devanand, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Acadia Pharmaceuticals - Consultant/Advisory Board
BioXcel - Consultant/Advisory Board
Eisai - Consultant/Advisory Board
GSK - Consultant/Advisory Board
Karuna - Grant/Research Support

Upregulation of tRF-19-J in Anti-A β Therapy-Related ARIA Among Alzheimer's Disease Patients and Its Role in Promoting Ubiquitin-Mediated Degradation of Connexin 43 in Brain Endothelial Cells

Min Fang, PhD *has nothing to disclose.*

Divergent latent classes of cognitive decline in the A4 and LEARN studies

Runpeng Li, PhD *has nothing to disclose.*

Associations between epigenetic and inflammatory aging, cognitive function, and blood-based biomarkers of Alzheimer's disease: findings from the INSPIRE-T cohort

Laure Rouch, PharmD, PhD *has nothing to disclose.*

Modified titration of donanemab reduced ARIA-E risk and maintained amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6

Hong Wang, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Eli Lilly and Company - Employee/Owner, Ownership/Stock options

3-23-DEV Developing Topics on Tau Biomarkers

Plasma p-tau217 Predicting Concurrent A β and Longitudinal Tau Across the Brain

Xi Chen, PhD *has nothing to disclose.*

LC-EC Tract Degeneration is associated with Entorhinal Tau and Memory in Autosomal-dominant Alzheimer's Disease

Elouise A. Koops, PhD *has nothing to disclose.*

Variations in Plasma p-tau217 by Sociodemographic Factors Across World Regions in a Preclinical AD Clinical Trials Program: the AHEAD 3-45 Study

Doris P Molina-Henry, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alzheimer's Association - Grant/Research Support

American Heart Associate - Grant/Research Support

NIH and NIA - Grant/Research Support

Rates of Progression to Tau-PET Positivity in Preclinical Alzheimer's Disease

Alexis Moscoso Rial, PhD *has nothing to disclose.*

A comparison of four fully automated platforms for the measurement of plasma p-tau217 in the Alzheimer's disease continuum

Marisa N. Denking, PhD *has nothing to disclose.*

Clinical performance and effect of pre-analytical variation of plasma pTau217 alone versus the plasma pTau217/A β 42 ratio for the identification of amyloid pathology

Marc Suárez-Calvet, PhD *has nothing to disclose.*

Discrepant tau-PET signal between [18 F]FTP and [18 F]MK6240 in low tau individuals

Cécile Tissot, PhD *has nothing to disclose.*

Cerebrospinal fluid MTBR243 tau correlates with [18 F] GTP1 Tau PET and the two biomarkers show similar correlations with clinical measures

Philip B. Verghese, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

C2N Diagnostics, LLC - Employee/Owner

Longitudinal relationships between systemic inflammatory markers, plasma p-tau181 and entorhinal tau Positron Emission Tomography (PET)

Koral V Wheeler, MS *has nothing to disclose.*

3-24-FRS-A Risk Factors and Biological Mechanisms for Cognitive Decline and Dementia in India

Risk and protective factors of cognitive decline in older adults from a nationally representative sample in India: Results from the LASI-DAD

Alden L. Gross, PhD, MHS *has nothing to disclose.*

Associations Between Brain Microstructure, Cognition and Socioeconomic Factors in a Diverse Cohort : the LASI-DAD Study

Yingxu Liu *has nothing to disclose.*

Associations between neurodegenerative plasma biomarkers and cognitive functioning and decline in India

Emma Nichols, PhD *has nothing to disclose.*

Hearing Loss and Cognition Among Older Adults in the Longitudinal Aging Study in India-Diagnostic Assessment of Dementia (LASI-DAD) Study.

Nicholas S Reed, AuD PhD *has nothing to disclose.*

Multilingual profiles and their association with cognition and brain structure among older Indian adults

Miguel Arce Renteria, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

NIA - Grant/Research Support

Gene-centric analysis using functional annotation identifies genetic associations with blood-based biomarkers of Alzheimer's disease in older adults from India

Jennifer A Smith, PhD, MPH *has nothing to disclose.*

3-25-FRS-B Language as a Lens: Investigating Cognitive Processes Across Linguistic Contexts

Bilingualism and Naming in MCI and Alzheimer's Disease: Insights from Catalan-Spanish Speakers

Marco Calabria, PhD *has nothing to disclose.*

Speech timing metrics as cross-linguistic markers of Alzheimer's and cognitive decline: Evidence from Kiswahili, Spanish, and Portuguese speakers

Adolfo M Garcia, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

TELL Toolkit SA - Ownership/Stock options

Patterns of breakdown of reading and spelling in a non-alphabetic language: a study in Bengali

Amitabha Ghosh, MD, FRCP *has nothing to disclose.*

Cross-linguistic characterization of speech and language profiles of English, Chinese, and Italian Primary Progressive Aphasia patients: a data-driven approach.

Gaia Chiara Santi, PhD *has nothing to disclose.*

Digits Across Languages: The Role of Lexical and Numerical Characteristics in Digit Span Performance Across Fourteen Languages

Boon Lead Tee, MD, MS *has nothing to disclose.*

3-26-PER-A Improving Clinical Trials for Atypical Alzheimer's Disease: A Call to Action

Enhancing Trial Design for Atypical AD

Paul S. Aisen, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Merck, Roche, Genentech, Abbvie, Biogen, ImmunoBrain Checkpoint, AltPep, Alector, Arrowhead and Neurimmune. - Consultant/Advisory Board
NIH, the Alzheimer's Association, Lilly and Eisai, and consults with Merck, Roche, Genentech, Abbvie, Biogen, ImmunoBrain Checkpoint, AltPep, Alector, Arrowhead and Neurimmune - Grant/Research Support

Introductory notions on atypical Alzheimer's disease

Nick Corriveau-Lecavalier, PhD *has nothing to disclose.*

Clinical Progression: Insights from Longitudinal Studies

Renaud La Joie, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

GE healthcare - Consultant/Advisory Board

Advocacy and Raising Awareness for Atypical AD

CHUKWUANUGO OGBUAGU, MD, MSc, PhD *has nothing to disclose.*

Digital Language Markers Differentiate Atypical Alzheimer's Disease Variants: Insights into Cognitive and Anatomical Mechanisms

Neguine Rezaii, MD *has nothing to disclose.*

Neuroimaging in Atypical AD: Considerations for Clinical Trials

Jennifer L. Whitwell, PhD *has nothing to disclose.*

3-27-PER-A Molecular subtyping in ADRD to unravel complex biology

Multi-omics studies reveal convergent and divergent pathways in Alzheimer's and related disorders

Mariet Allen, PhD *has nothing to disclose.*

Leveraging proteomics to decipher molecular subtypes of ADRD

Lenora A Higginbotham, MD *has nothing to disclose.*

Multiomics studies identify disease trajectories in AD

Yasser Iturria-Medina *has nothing to disclose.*

Single cell omics reveal cell-specific subtypes of AD and aging

Vilas Menon, PhD *has nothing to disclose.*

Molecular subtypes of Alzheimer's disease

Betty Tijms *has nothing to disclose.*

Molecular subtypes in Alzheimer's disease - transcriptome and beyond

Bin Zhang, PhD *has nothing to disclose.*

3:30-4:15 pm

3-A-GEP Guided Electronic Poster Tour: Unraveling Sleep and Alzheimer's Disease: Exploring Biomarkers, Glymphatic Function, and Longitudinal Sleep Dynamics Across the Continuum

The Association between Sleep Disturbances, Imaging Biomarkers and Cognitive Decline along the Trajectory of Alzheimer's Disease

Reihaneh Ahmadi, PhD *has nothing to disclose.*

Monday-221 Reliability of longitudinal sleep monitoring in amyloid-negative and amyloid-positive older adults.

Taylor J Pedersen, BS *has nothing to disclose.*

Sunday-118 Reduction of slow wave activity during deep sleep in the Alzheimer's disease continuum

Núria Tort-Colet, PhD *has nothing to disclose.*

Sunday-232 Associations of Sleep Quality and Apolipoprotein Genotype with Blood-based Biomarkers of Alzheimer's Disease and Neurodegeneration

Tina T. Vo, PhD *has nothing to disclose.*

3-B-GEP Guided Electronic Poster Tour: The many roles and influences of caregivers in Alzheimer's disease: parents, spouses, friends, and bots

Parental Influence: Childhood caregiver well-being associates with epigenetic aging among older adults

Shana D. Stites *has nothing to disclose.*

Monday-648 Gossiping Robots: A Novel Approach to Enhancing Engagement and Well-Being in Dementia Care

Arshia A Khan, Ph.D. *has nothing to disclose.*

Sunday-635 Community support utilization by Black dementia caregivers: key factors

Florence U Johnson, PhD, RN *has nothing to disclose.*

Sunday-636 Racially and Ethnically Diverse Sexual and Gender Minority Dementia Caregivers: Findings from the Qcare Study

Krystal R. Kittle, PhD *has nothing to disclose.*

4:15-5:45 pm

3-28-PER-B Women's brain health across the lifespan: insights into aging and dementia

Sex and gender differences in cognitive resilience

Eider M Arenaza-Urquijo, PhD *has nothing to disclose.*

Unveiling the X Chromosome's Role in Alzheimer's Disease

Rachel F. Buckley, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

NIH - Grant/Research Support

Women's Brain Health Initiative - Consultant/Advisory Board

Women's Health Steering Committee - Consultant/Advisory Board

Estrogen Deprivation and Risk of Dementia

Walter A. Rocca, MD, MPH *has nothing to disclose.*

Women in ADRD: Addressing Disparities in Diagnosis and Care

Tamlyn J Watermeyer, PhD *has nothing to disclose.*

3-29-ECBS Emerging Concepts in Basic Science: Panel Discussion

Panel Discussion and Q&A

Thomas G Beach *has nothing to disclose.*

Panel Discussion and Q&A

Carole Escartin, PhD, HDR *has nothing to disclose.*

Panel Discussion and Q&A

Veronica Galvan, PhD *has nothing to disclose.*

Panel Discussion and Q&A

Maria Grazia Spillantini *has nothing to disclose.*

Panel Discussion and Q&A

Shin Kang, PhD *has nothing to disclose.*

Panel Discussion and Q&A

Michelle M Mielke, Ph.D. *has nothing to disclose.*

Panel Discussion and Q&A

Tony Wyss-Coray, PhD *has nothing to disclose.*

3-30-FRS-A Disease insights from Amyloid PET and its implications for trials and clinical practice

Quantifying natural amyloid plaque accumulation using disease progression modeling with ADNI, BioFINDER, and LEARN datasets

Kay Hoong Chow, BSc *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eli Lilly - Employee/Owner

Sex, education and race/ethnicity have distinct effects on amyloid and tau-PET status

Colin Groot, PhD *has nothing to disclose.*

Total-body PET Amyloid Signal in the Liver in Alzheimer's Disease

Emily N. Holy, BS *has nothing to disclose.*

Association of Occipital Amyloid PET Burden with ARIA-E: Exploratory Analyses in Three Clinical Trials of Donanemab

Ian A. Kennedy, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eli Lilly and Company - Employee/Owner, Ownership/Stock options

Capturing Alzheimer's Disease Heterogeneity With Spatially Independent Patterns of Amyloid Accumulation

Leonard Pieperhoff, MSc *has nothing to disclose.*

Amyloid PET and changes in clinical management among ethnoracially diverse and clinically atypical individuals: Findings from New IDEAS

Charles C. Windon, MD *has nothing to disclose.*

Early Tau and Amyloid Co-Pathology Linked to Basal Forebrain Atrophy in Cognitively Unimpaired Older Individuals

Ying Xia, PhD *has nothing to disclose.*

3-31-PER-B Looking Backward and Looking Forward - A reflection on 25 years of Alzheimer's Disease Research with Lessons for Future Progress

Systematic review and meta-analysis of Alzheimer's disease clinical trial results over more than a quarter century (1994-2025) - overall evidence and time savings

Samuel P. Dickson, Ph.D *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Pentara Corporation - Employee/Owner

An overview of the consortia, non-profit groups and other organizations in the Alzheimer's advocacy space over the past quarter century

Phyllis Barkman Ferrell, DrPH, MBA *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alzheimers Drug Discovery Foundation - Consultant/Advisory Board

Cognito - Consultant/Advisory Board

Davos Alzheimer's Collaborative - Consultant/Advisory Board

Gates Ventures - Consultant/Advisory Board

Global Alzheimer's Platform - Consultant/Advisory Board

Lilly - Ownership/Stock options

Linus Health - Consultant/Advisory Board

Morningside Technology Advisory - Consultant/Advisory Board

Not Impossible Labs - Consultant/Advisory Board

SiteRx - Consultant/Advisory Board

StartUp Health - Consultant/Advisory Board

Capturing cognitive efficacy in Alzheimer's disease clinical trials. A review of the last 25 years.

John E Harrison, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Actinogen - Consultant/Advisory Board

Altoida - Consultant/Advisory Board

Boehringer Ingelheim - Consultant/Advisory Board

Cambridge Cognition - Consultant/Advisory Board

Centessa - Grant/Research Support

Cognito Therapeutics - Consultant/Advisory Board

Julius Clinical - Grant/Research Support

Kynexis - Consultant/Advisory Board

Metis Cognition Ltd. - Employee/Owner

Novartis - Consultant/Advisory Board

Pearson - Consultant/Advisory Board

Prilenia - Consultant/Advisory Board

Scottish Brain Sciences - Employee/Owner

Shionogi - Consultant/Advisory Board

Therini - Consultant/Advisory Board

The evolving roles of imaging and fluid biomarkers for Alzheimer disease over the past quarter century

Laura Ibanez, PhD *has nothing to disclose.*

Reflection on Statistical Innovations in The Past 25 Years of Alzheimer's Disease Research

Craig Mallinckrodt, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Pentara Corporation - Employee/Owner

3-32-FRS-A How Generalizable are Alzheimer's Disease Biomarker Relationships?

Sociodemographic associations with AD biomarkers in POINTER, UBRAIN, and ADNI

Carmen M Colceriu, MSc *has nothing to disclose.*

White matter hyperintensities and Alzheimer's disease pathology in heterogeneous cohorts

Theresa M. Harrison, PhD *has nothing to disclose.*

Does cohort heterogeneity affect relationships between AD biomarkers and cognition?

Peiwei Liu, PhD *has nothing to disclose.*

Risk factors and clinical relevance of MRI vascular markers in the U.S. POINTER study: a cross-cohort comparison with the Framingham Heart Study

Pauline Maillard, PhD *has nothing to disclose.*

Evaluation of Alzheimer's disease biomarkers and cognition in non-Hispanic Black and non-Hispanic White participants in ADNI and US POINTER Imaging

Talia L. Robinson, PhD *has nothing to disclose.*

Heterogeneity in associations between short sleep duration and amyloid PET: Comparing US POINTER and A4

Joseph R. Winer, PhD *has nothing to disclose.*

3-33-FRS-A Prevention of cognitive decline and dementia: exploring the effects of non-pharmacological interventions

A Randomized Study of a Government Cash Supplement on Cognitive Function among Adults in Malawi

Allison E Aiello, PhD *has nothing to disclose.*

A Multi-Modal Medical Management and Lifestyle Randomized Clinical Trial Increases Cerebral Blood Flow and Lowers Diabetic Risk in Persons with Early Alzheimer's Disease: Results from The [PREVENTION] Trial

Jennifer E. Bramen, PhD *has nothing to disclose.*

Walking to Protect Against Cognitive Decline: The Role of APOE Genotype, Sex, and Race

Joel S Burma, PhD *has nothing to disclose.*

Effects on blood neurodegeneration biomarkers of a randomized hearing rehabilitation intervention: ACHIEVE Clinical Trial update

Josef Coresh, MD, PhD *has nothing to disclose.*

Long-term adherence to lifestyle changes and association with cognitive change: 11-year results from the FINGER randomized, controlled trial

Miia Kivipelto, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Combinostic - Consultant/Advisory Board

Lilly - Consultant/Advisory Board

Nestle - Consultant/Advisory Board

NovoNordisk - Speakers Bureau/Honoraria for non-CME

Nutricia - Speakers Bureau/Honoraria for non-CME

Diversity in United States dementia prevention trials: An updated systematic review of eligibility criteria and recruitment strategies

Najoua Lazaar, MSc *has nothing to disclose.*

3-34-DEV Developing Topics on Pre-existing Conditions

Recombinant Zoster Vaccine Associated with a Reduced Risk of Dementia Onset among US Beneficiaries ≥65 Years of Age

Hannah Alsdurf, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

GSK - Employee/Owner, Ownership/Stock options

Association between Alzheimer's Disease Blood-Based Biomarkers and Depressive Symptoms

Julia R. Bacci, BA *has nothing to disclose.*

MIND diet intervention for cognitive function in new-onset mild stroke: a pilot randomized controlled trial

Hui Chen, PhD *has nothing to disclose.*

The APPLE Tree programme randomised controlled trial: Effect of Active Prevention in People at risk of dementia through Lifestyle, bEhaviour change and Technology to build REsiliEnce

Harriet Demnitz-King, PhD *has nothing to disclose.*

One Size Does Not Fit All: Menopause Hormone Therapy Type and Route of Administration Influences Cognitive Health

Laura Gravelsins, PhD *has nothing to disclose.*

Longitudinal Increases in Physical Frailty are Linked to Accelerated Cognitive Decline, Independent of Preclinical Amyloid Pathology

Paola A. Matos, BS *has nothing to disclose.*

Associations between Early-Life Area-Level Disadvantage and Plasma Markers of Alzheimer's Disease Pathology and Neurodegeneration – A Mixed-Longitudinal Study

Jason F Moody, PhD *has nothing to disclose.*

Association Between Early Life Farming Exposure and Alzheimer's Disease Neuropathology

W. Ryan Powell, PhD, MA *has nothing to disclose.*

Recombinant zoster vaccine is associated with lower risk of dementia in adults aged ≥ 65 years

Emily Rayens, PhD, MPH *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AstraZeneca - Grant/Research Support

F2G, Inc. - Grant/Research Support

GlaxoSmithKline - Grant/Research Support

Moderna - Grant/Research Support

3-35-FRS-B Studying tissue samples from rare cohorts to learn about early stage AD pathophysiology.

Normal pressure hydrocephalus – potentially treatable dementia and window for living human brain

Ville Leinonen, PhD, MD *has nothing to disclose.*

Cell states associated with amyloid pathology and cognitive resilience in living human brain

Evan Macosko, MD, PhD *has nothing to disclose.*

Biopsies from Idiopathic Normal Pressure Hydrocephalus Patients as a Window to the Events of Early Alzheimer's disease: Beta-amyloid and Tau Pathologies Alter Synaptic Transmission in Human Brain

Tarja Malm, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

NovoNordisk - Speakers Bureau/Honoraria for non-CME

Single Cell Transcriptomics of Paired CSF and Blood Immune Populations Reveals Unique Macrophage Population with Relevance to Alzheimer's Disease

Beth Stevens, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Annexon Biosciences - Consultant/Advisory Board

Genentech - Consultant/Advisory Board

Neumora Therapeutics - Non-Mutual funds Stock

Nico - Non-Mutual funds Stock

Biofluid-based biomarker discovery using brain biopsy data as the reference standard

Henrik Zetterberg, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics,

AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothen -
Consultant/Advisary Board
Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD -
Speakers Bureau/Honoraria for non-CME

3-36-FRS-A Genome wide association studies of deep phenotypes

Influence of PLEK Genetic Variants on Brain Glucose Metabolism

Marco De Bastiani *has nothing to disclose.*

GIGAVCID: A Genome-Wide Meta-Analysis of 1.1 Million Individuals Identifies Novel Genetic Loci for Vascular Cognitive Impairment

Bernard Fongang, PhD *has nothing to disclose.*

Association of whole genome sequencing variants with time to Alzheimer's disease

Xueqiu Jian, PhD *has nothing to disclose.*

Charactering the interaction between expression quantitative trait loci and Alzheimer's Disease Status

Makaela Mews, BS *has nothing to disclose.*

Whole-genome variant analysis of Alzheimer's disease biomarker traits

Lu Shen, PhD, MD *has nothing to disclose.*

Polygenic risk scores modify the association between amyloid and tau PET accumulation in patients with Alzheimer's disease

Carolina Valentim *has nothing to disclose.*

Wednesday, July 30, 2025, AAIC Disclosures

8:00-8:45 am

4-2-LPR Integrative omics studies unravels pathomechanisms in Alzheimer's disease and related dementia

Epigenetic age acceleration is faster in Black adults and is associated with plasma amyloid

Rory Boyle *has nothing to disclose.*

Network-Based Integrative Single-Nucleus Multi-Omics Analysis Reveals Cell Type-Specific Metabolic Rewiring and Potential Drug Targets for Alzheimer's Disease

Yunguang Qiu, PhD *has nothing to disclose.*

Machine Learning-Based Multi-omic Analyses of UK Biobank Identify Genes and Pathways Implicated in Alzheimer's Disease

Maryam Samieinasab, PhD *has nothing to disclose.*

Wednesday-089 Unraveling High-Risk Cell-Cell Interactions in Alzheimer's Disease Using an Integrative Single Cell Analysis.

Jiahui Liu, MS *has nothing to disclose.*

Wednesday-095 Brain telomere length associates with hippocampal ptau and is mediated by DNA methylation

Nadia Dehghani *has nothing to disclose.*

Wednesday-153 Vulnerability of the Myelin-Axon Interface Uncovered by Subcellular Proteomics and Imaging of Alzheimer's Human Brain

Yifei Cai *has nothing to disclose.*

4-3-LPR The range of economic impacts of dementia

Tracking the Economic Burden of Dementia: Changes in Care Costs and Spending Elasticity Relative to GDP and Per Capita Health Expenditure

YUE DONG, BSN *has nothing to disclose.*

Transformer deep learning architectures for health economic modelling of novel therapies for Alzheimer's disease

Linus Jönsson, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eli Lilly - Consultant/Advisory Board

H. Lundbeck - Consultant/Advisory Board

Novo Nordisk - Grant/Research Support

TEVA - Consultant/Advisory Board

Can primary prevention of Alzheimer's disease be cost-effective?

Soeren Mattke, MD, DSc *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alzpath - Consultant/Advisory Board

Biogen - Consultant/Advisory Board

Boston Millenia Partners - Consultant/Advisory Board

C2N - Consultant/Advisory Board

Eisai - Consultant/Advisory Board

Eli Lilly - Consultant/Advisory Board

Novartis - Consultant/Advisory Board

Roche/Genentech - Consultant/Advisory Board

Senscio Systems -

Estimated effects of onset of dementia on labor market

Maria Prados, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biogen -

The journey of the patients with dementia in the Peruvian health system

Daniela Rossini Vilchez, Ba *has nothing to disclose.*

Wednesday-787 Employment, Volunteering, and Health-Related Resource Use in Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study

Carolyn W. Zhu, PhD *has nothing to disclose.*

4-4-DEV Developing Topics on Innovative therapeutic approaches

Effects of Obicetrapib, a Potent Oral CETP Inhibitor, on Alzheimer's Disease Biomarkers in 1727 Patients with cardiovascular disease

Philip Scheltens, MD, PhD *has nothing to disclose.*

Donanemab in Early Symptomatic Alzheimer's Disease: Efficacy and Safety from the TRAILBLAZER-ALZ 2 Long-Term Extension

John R. Sims, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eli Lilly and Company - Employee/Owner, Ownership/Stock options

Microglial Activation Correlates with Amyloid Clearance and Cognitive Benefit in Lecanemab-Treated Early AD Patients

Hui-dong Tang, PhD, MD *has nothing to disclose.*

The Lecanemab Clarity AD Open-Label Extension in Early Alzheimer's Disease: Initial Findings From the 48-Month Analysis

Christopher H van Dyck, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biogen - Grant/Research Support

BMS - Consultant/Advisory Board

Cerevel - Consultant/Advisory Board, Grant/Research Support

Eisai - Consultant/Advisory Board, Grant/Research Support

Eli Lilly - Grant/Research Support

Genentech - Grant/Research Support

Janssen - Grant/Research Support

Ono - Consultant/Advisory Board

Roche - Consultant/Advisory Board, Grant/Research Support

UCB - Consultant/Advisory Board, Grant/Research Support

4-5-DEV Developing Topics on Molecular Biology and Neuropathology

Cell-cell signaling drives a pathologic astrocyte state contributing to cognitive decline in Alzheimer's Disease

Natacha Comandante-Lou, PhD *has nothing to disclose.*

Neurons accumulate disease-specific somatic deletions across tau pathological states in Alzheimer's disease

Michael B Miller, MD, PhD *has nothing to disclose.*

Myocardial sympathetic distal axon loss in subjects with Lewy pathology: an artificial intelligence-based histopathological analysis

Liisa Myllykangas, MD, PhD *has nothing to disclose.*

Fetomaternal transfer during Down Syndrome pregnancies induces maternal cognitive decline in an APP-dependent manner

Eitan Okun, PhD *has nothing to disclose.*

4-6-LPR Unveiling cognitive enigmas with intelligent assessment and AI

A Multidomain Lifestyle Intervention in Dutch Older Adults to Prevent Cognitive Decline (FINGER-NL): from RCT to follow-up study

Sebastian Köhler, PhD *has nothing to disclose.*

Predicting cognitive impairment using novel functional features of spatial proximity and circularity in the digital clock drawing test

Adlin Pinheiro, MA *has nothing to disclose.*

Wednesday-705 Leveraging electronic health records to examine outcome disparities in people with Alzheimer's Disease

Shruthi Venkatesh, BS *has nothing to disclose.*

Wednesday-770 Barriers and facilitators for the implementation of an integrated evaluation for older adults including a digital cognitive tool in primary care settings in Mexico City

Mariana López-Ortega, PhD *has nothing to disclose.*

Wednesday-814 Hippocampal vascularization is associated with greater efficiency during a remote real world wayfinding training in older adults

Jonas Marquardt, M.Sc. *has nothing to disclose.*

4-7-FRS-D Exploring Cognitive and Psychosocial Determinants of Dementia Outcomes II

Association between structural and social determinants of health and cognitive functioning and African Americans in the ARCHES cohort

Ganesh M. Babulal, OTD, PhD *has nothing to disclose.*

Discrepancies in Dementia Severity Perceptions: Exploring the Agreement Between Care Partners and Clinical Assessments

Paige DiStefano, MS, CCC-SLP *has nothing to disclose.*

Psychological, environmental, and biological factors linked to cognitive decline in Black older adults: a multi-level approach from the Minority Aging Research Study (MARS)

Juliana Nery Souza-Talarico, PhD *has nothing to disclose.*

4-8-LPR Functional studies to reveal novel disease mechanisms in Alzheimer's disease and related dementia

Sleep-wake variation in body temperature regulates tau phosphorylation, secretion and splicing

Geoffrey CANET, PhD *has nothing to disclose.*

Investigating the effects of NOTCH3 Asian-specific mutant on blood-brain-barrier using patient iPSC-derived cell types

Jolene Wei Ling Lee *has nothing to disclose.*

Pioneering iPSC-Based Therapies for Dementia: Enhancing Safety and Microenvironment Integration

Sofia Gomes Lopes, Bachelor's in Biomedical Technology *has nothing to disclose.*

Wednesday-090 High-throughput CRISPR screen of GWAS risk loci in human microglia reveals novel risk genes for Alzheimer's disease and multiple sclerosis

Michael D Gallagher *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
CRISPR Therapeutics - Non-Mutual funds Stock

Intellia Therapeutics - Non-Mutual funds Stock

Pfizer - Non-Mutual funds Stock

Wednesday-156 Characterization of myelin compromise in rats with Alzheimer's-like tauopathy

AI LIU *has nothing to disclose.*

Wednesday-207 Effect Of Apoe Isoform And Lipidation On Clearance Of Amyloid Beta Monomers, Oligomers, And Fibrils By Human Astrocytes

Kamila Nurmakova *has nothing to disclose.*

4-9-LPR Emerging technologies in dementia care

Usage and Feasibility of Web Applications in Speech-Language Therapy: Insights from the Communication Bridge 2 Trial for Primary Progressive Aphasia

Ollie Fegter, MA *has nothing to disclose.*

Supera Cognitive Stimulation Study effectiveness of a multicomponent cognitive intervention for cognitively unimpaired older adults: a randomized clinical controlled trial partial data

Thais Bento Lima-Silva, PhD. *has nothing to disclose.*

Self-powered wearable medical devices for cognitively impaired older adults

Morteza Sabet, PhD *has nothing to disclose.*

Wednesday-587 Cognitive Rehabilitation Programs for Older Adults with dementia using Digital Voice Assistants

Paul S Jansons, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Deakin University - Employee/Owner

Wednesday-598 Computerized Working Memory Training vs Active Control in Mild Cognitive Impairment

Trine Holt Edwin, MD, PhD *has nothing to disclose.*

Wednesday-616 Balance or movement confidence: exergame targets for people living with dementia

Erica Dove, MSc *has nothing to disclose.*

9:00-10:30 am

4-11-FRS-B Multiomic approaches to understanding clinical and neuropathological heterogeneity in Alzheimer's disease

Integrative multi-omics analysis reveals physiological and genetic drivers of CSF biomarker variability: implications in neurodegeneration studies

Pablo García-González, MSc *has nothing to disclose.*

Molecular insights into shared and distinct etiologies of Alzheimer's disease and major depressive disorder at single-nucleus resolution

Michael W Lutz, PhD *has nothing to disclose.*

Integrated Transcriptome-Wide and miRNA Sequencing Analysis of Systemic Infection in Alzheimer's Disease Brain

Giulia Pegoraro *has nothing to disclose.*

Epigenomic subtyping of late-onset Alzheimer's disease reveals distinct microglial signatures and molecular inflammatory phenotypes

Ehsan Pishva, MD, PhD *has nothing to disclose.*

Plasma Proteomics of Cognitive Resilience to ADRD: The ARIC Study

Alvin G. Thomas, PhD *has nothing to disclose.*

4-12-CTB-A Bedside diagnosis, management, and prognosis communication of primary tauopathies progressive supranuclear palsy and corticobasal syndrome

Clinical detection of PSP, not only an "atypical parkinsonism"

Blas Couto, MD, PhD *has nothing to disclose.*

Clinical detection of corticobasal syndrome, beyond an "atypical" Alzheimer's

Ignacio Flores, MD, PhD *has nothing to disclose.*

Use of biomarkers to differentiate 4-repeat tauopathies from AD

Indira Ruth Garcia Cordero, PhD *has nothing to disclose.*

Pharmacological management of tauopathies

Raul Medina Rioja, MD *has nothing to disclose.*

Management of neurobehavioral changes in PSP

Alonso Morales-Rivero, MD *has nothing to disclose.*

Communication of prognosis to patient with PSP and family

Juan-Camilo Vargas-González, Ph.D., MSc, M.D. *has nothing to disclose.*

4-13-FRS-C Lecanemab Subcutaneous Formulation for Maintenance Dosing: The Potential of a New and Convenient Option for Ongoing Treatment in Early Alzheimer's Disease

Subcutaneous Lecanemab: Potential Benefits and Place in Therapy

Sharon Cohen *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AbbVie - Grant/Research Support
AgeneBio - Grant/Research Support
Alnylam - Grant/Research Support, Consultant/Advisory Board
Alzheon - Grant/Research Support
Anavex - Grant/Research Support
Biogen - Grant/Research Support, Consultant/Advisory Board
Biohaven - Consultant/Advisory Board
BMS - Grant/Research Support, Consultant/Advisory Board
Cassava Sciences - Grant/Research Support, Consultant/Advisory Board
Cognivue - Consultant/Advisory Board
Cogstate - Consultant/Advisory Board
Eisai - Grant/Research Support, Consultant/Advisory Board
Eli Lilly - Grant/Research Support, Consultant/Advisory Board
GAP - Grant/Research Support
GSK - Grant/Research Support, Consultant/Advisory Board
INmune Bio - Grant/Research Support
INmune Bio - Consultant/Advisory Board
Janssen - Grant/Research Support
Kisbee Therapeutics - Consultant/Advisory Board
Lundbeck - Consultant/Advisory Board
Novartis - Consultant/Advisory Board
Novo Nordisk - Grant/Research Support, Consultant/Advisory Board
Parexel - Consultant/Advisory Board
RetiSpec - Grant/Research Support, Consultant/Advisory Board
Roche - Grant/Research Support
SciNeuro Pharmaceuticals - Consultant/Advisory Board
UCB Biopharma - Grant/Research Support

Clinical and Pharmacologic Profile of a Subcutaneous Lecanemab Formulation

Michael C. Irizarry, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai Inc - Employee/Owner

Development of Subcutaneous Lecanemab: Establishing the Comparability of Subcutaneous and Intravenous Lecanemab Formulations

Natasha Penner, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai Inc. - Employee/Owner

Lecanemab Subcutaneous Formulation for Maintenance Dosing in Early Alzheimer's Disease (AD)

Larisa Reyderman, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

4-14-FRS-A Chronic Traumatic Encephalopathy (CTE): Clinical aspects, pathophysiology and biomarkers compared to ADRD

Unrecognized Repetitive Head Impact Exposure Among Older Adults Across Three Alzheimer's Disease Research Centers

Breton M. Asken, PhD, ATC *has nothing to disclose.*

A unique pattern of T2 FLAIR white matter hyperintensities and related co-localizing neuropathology associated with repetitive head impacts

Jenna R. Groh, BA *has nothing to disclose.*

Investigation of enlarged perivascular spaces as a biomarker for head impact exposure across two independent cohorts

Suzie Kamps, MSc. *has nothing to disclose.*

Validity of the 2021 Traumatic Encephalopathy Syndrome Criteria for CTE pathology

Jesse Mez, MD, MS *has nothing to disclose.*

TDP-43 related mis-splicing and decreased protein levels of synapse related genes are associated with cognitive impairment in chronic traumatic encephalopathy

Thor D. Stein, MD, PhD *has nothing to disclose.*

The Inflammatory Signature of RHI in Athletes at Risk of CTE

Carmela Tartaglia, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

EISAI - Consultant/Advisory Board

Lilly - Consultant/Advisory Board

Novo Nordisk - Consultant/Advisory Board

4-15-FRS-A Artificial Intelligence-Focused Advancements in ADRD Diagnosis and Care

Artificial Intelligence in Diagnosis and Management of Alzheimer's Disease and Related Dementias: Evaluation of FDA Device Regulation

Krista Y. Chen, BS *has nothing to disclose.*

Enhanced Detection of Dementia in the Emergency Department Through Advanced Machine Learning Techniques

Inessa Cohen, MPH *has nothing to disclose.*

Advancing Dementia Research Recruitment with AI-Driven Insights and Behavioral Nudges

Jessica Andrea Hernandez Chilatra, BSN *has nothing to disclose.*

Development and validation of the DCOS (Digitalised Combined Objective-Subjective cognitive screening): A five-minute neuropsychological test for mild neurocognitive disorder

Bonnie Y.K. Lam, PhD *has nothing to disclose.*

Spatio-temporal digital markers of behavioural and psychological symptoms to support clinical dementia care

Leia Shum, MASc *has nothing to disclose.*

Cognitive Assessment of Dementia Patients Using Large Language Models

Jie Yang, PhD *has nothing to disclose.*

4-16-PER-B Tailored Exercise Interventions for Dementia prevention: bridging research evidence and primary care practice: TEIDe Consortium.

TEIDe Consortium as a model to move towards a personalized medicine approach for the prevention of cognitive impairment and dementia

Irene Esteban-Cornejo, PhD *has nothing to disclose.*

Reshaping the path of mild cognitive impairment by refining exercise prescription: A trial designed to understand the type of exercise, for whom, and how.

Teresa Liu-Ambrose, PhD, PT *has nothing to disclose.*

Relating Physical Activity to Cognitive Function, Brain Morphology, and AD-related Blood Biomarkers: Preliminary Findings from the IGNITE study

Lauren Oberlin, PhD *has nothing to disclose.*

Resistance exercise for optimizing cognitive function during aging: the role of individual characteristics.

Patricio Solis-Urra, PhD *has nothing to disclose.*

Ameliorating aging-associated cognitive decline by physical exercise: multi-organ integrative approach (EMBRACE & AMETHYST trials from Slovakia).

Barbara Ukropcová, prof, MD, PhD *has nothing to disclose.*

4-17-DEV Lysosome regulation and signaling in aging and Alzheimer's disease.

Genetic dissection of TMEM106B in tauopathy

Joanna L Jankowsky, PhD *has nothing to disclose.*

Lysosomal pH regulation in aging and neurodegenerative disease

Aimee W Kao, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eli Lilly & Co. - Grant/Research Support

Ono Pharmaceuticals - Grant/Research Support

Pharmacological enhancement of autophagy mitigates tau pathology in a stem cell model

Celeste M. Karch, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai - Consultant/Advisory Board, Grant/Research Support

NIH - Grant/Research Support

Tau Consortium - Grant/Research Support

Modulating TFEB lysosomal function for aging and Alzheimer's disease

Marco Sardiello, PhD *has nothing to disclose.*

A TFEB-lysosomal pH signaling pathway in tauopathy

Hui Zheng, PhD *has nothing to disclose.*

4-18-FRS-C Neural circuit hyperexcitability and epileptic manifestations at the intersection of Alzheimer's disease pathobiology and aging

Neuronal hyperexcitability and impaired spatial coding in Alzheimer's disease mouse models

Abid Hussaini, MS, PhD *has nothing to disclose.*

The ELUCID Study: Identifying mechanisms and risk factors for dementia in individuals with late-onset unexplained epilepsy

Alice D Lam, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Acadia Pharmaceuticals - Consultant/Advisory Board

Neurona Therapeutics - Grant/Research Support, Consultant/Advisory Board

Neural circuit hyperexcitability, amyloid-beta (A β), tau, and neurodegeneration in patients with early-stage Alzheimer's disease

Kamalini G Ranasinghe, MD PhD *has nothing to disclose.*

Neurophysiological signatures of default mode network dysfunction and cognitive decline in Alzheimer's disease.

Mouhsin Shafi, MD, PhD *has nothing to disclose.*

11:00-12:15 pm

4-10-PL Plenary Session

Restoring Hippocampal Glucose Metabolism Rescues Cognition Across Alzheimer's Disease Pathologies

Katrin I. Andreasson, MD *has nothing to disclose.*

4-10-PL Plenary Session

Waking up to the importance of sleep in MCI and AD

Sharon L. Naismith, DPsych *has nothing to disclose.*

2:00-3:30 pm

4-19-FRS-B NIH/NIA-ADSP Artificial Intelligence and Machine Learning Consortium: Gene Discovery and Drug Development for Alzheimer's Disease

Human genetics and real-world patient data fuel target and drug discovery in Alzheimer's disease using Artificial Intelligence

Feixiong Cheng, PhD *has nothing to disclose.*

Genomic Frontiers in Alzheimer's Research: A Primer on the Alzheimer's Disease Sequencing Project and its AI/ML Opportunities

Emily Greenfest-Allen, PhD *has nothing to disclose.*

Evolutionary Action Reveals Sex-Specific Pathogenic and Protective Pathways and Differential Cell Involvement in Alzheimer's Disease

Olivier Lichtarge, MD, PhD *has nothing to disclose.*

Learning the Regulatory Code of Alzheimer's Genomes

Towfique Raj, PhD *has nothing to disclose.*

Unveiling the genetic architecture of white matter tracks through unsupervised deep representation learning of fractional anisotropy images

Degui Zhi, PhD *has nothing to disclose.*

4-20-FRS-A From multi-omics to multi-disease pathways in alzheimer's and related disorders

Mapping of immunome, brain imaging, and cognition in an aging cohort at risk for Alzheimer's disease

Wassim Elyaman, PhD *has nothing to disclose.*

Multiomic Evidence for a Unified Model of Alzheimer's Disease Etiology Linking Astrocyte-Neuron Lactate Shuttle Impairment and Microglial Flux Capacity

Cory C Funk, PhD *has nothing to disclose.*

iNeuron-GEM: Identifying Metabolic Alterations in Neuronal Subtypes Associated with Alzheimer's Disease Pathophysiology

Boyu Jiang *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Purdue University - Employee/Owner

post translational modifications in the brain are critical contributors to Alzheimer's disease neuropathology and cognitive decline

Julia B. Libby, BS *has nothing to disclose.*

CSF metabolomic signatures across five proteomic subtypes in patients with Alzheimer's disease

Georgia Malliou, MSc *has nothing to disclose.*

Spatial transcriptomics of cerebral amyloid angiopathy and amyloid- β related angiitis

Marcel Seungsu Woo, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Lilly - Speakers Bureau/Honoraria for non-CME

4-21-CTB-B Differential Diagnosis - If it's not Alzheimer's then what's next?

Lewy Body Dementia

Maria Cecilia Fernández, MD *has nothing to disclose.*

Normal Pressure Hydrocephalus (NPH)

David T. Jones, MD *has nothing to disclose.*

Frontotemporal Dementia

Julio C. Rojas, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Amylyx -

Eisai -

Eli Lilly -

Ferrer International - Consultant/Advisory Board

LATE

Seyed A Sajjadi, MD, PhD *has nothing to disclose.*

Vascular Dementia

Eric E. Smith, MD, MPH *has nothing to disclose.*

4-22-PER-B Innovations in Tau-Targeting Therapies and Biomarkers for Alzheimer's Disease: Bridging Research and Clinical Practice

Tau-targeting therapeutics: the next frontier in disease-modifying treatments for Alzheimer's disease

Szofia Bullain, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biogen - Employee/Owner

Advancing patient care with tau pathology biomarkers

Howard M Fillit, M.D. *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alector - Consultant/Advisory Board

Eli Lilly - Consultant/Advisory Board

Icahn School of Medicine at Mount Sinai - Employee/Owner

LifeWorx - Consultant/Advisory Board

Otsuka Lundbeck - Consultant/Advisory Board

The Key - Consultant/Advisory Board

Biomarker development for the tau therapeutic landscape

Danielle Graham, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biogen - Employee/Owner

Tau in Alzheimer's disease: Shaping the future patient journey

Douglas W. Scharre, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Avanir - Grant/Research Support

Biogen - Grant/Research Support

BioVie - Grant/Research Support

BrainTest - Consultant/Advisory Board

Cassava - Grant/Research Support

Cognition Therapeutics - Grant/Research Support

Cognitive Research Corporation - Grant/Research Support

Cognito - Grant/Research Support

EIP - Grant/Research Support

Eisai - Consultant/Advisory Board, Speakers Bureau/Honoraria for non-CME

Genetech - Grant/Research Support

Insightec - Grant/Research Support

Janssen - Grant/Research Support

Lilly - Grant/Research Support, Speakers Bureau/Honoraria for non-CME, Consultant/Advisory Board

Otsuka - Consultant/Advisory Board

Precision Medicine - Grant/Research Support

Premier Research Group - Grant/Research Support

Roche - Grant/Research Support

UCB Biopharma - Grant/Research Support

UniQure - Grant/Research Support

Vivoryon Therapeutics - Grant/Research Support

Overview of tau biology as it relates to Alzheimer's pathophysiology, symptoms, and therapeutic development

Lawren VandeVrede, MD, PhD *has nothing to disclose.*

4-23-DEV Developing Topics on Biomarker Advancements

Novel MTBR-specific immunoassays MTBR-1 and MTBR-pTau262 for assessment of tau pathology in Alzheimer's disease

Fernando Gonzalez-Ortiz, MD, MSc *has nothing to disclose.*

AT(N) Biomarkers Across Modalities in the Pathways Between Multimorbidity and Cognition

Xiaqing Jiang, PhD *has nothing to disclose.*

The remote Mobile Toolbox for capturing cognitive change in preclinical Alzheimer's disease

Roos J Jutten, PhD *has nothing to disclose.*

Pre-atrophic Neurodegeneration: A Novel MRI-Based Biomarker for Early Neuronal Injury Coincident with Early Amyloid Accumulation

Satya V.V.N. Kothapalli, PhD *has nothing to disclose.*

Longitudinal trajectories of advanced cortical diffusion-weighted imaging measures of tissue microstructure in pre-symptomatic autosomal dominant Alzheimer's disease

Christopher S Parker, PhD *has nothing to disclose.*

Biomarker-integrated Prognostic Stagings for Alzheimer's Disease

Daeun Shin, MD *has nothing to disclose.*

Sex-Specific Associations Between Systemic Inflammation and Brain Health in Aging: Evidence from a Multi-Ethnic Canadian Cohort

Katie L Vandelloo, MSc *has nothing to disclose.*

Comparison of plasma biomarkers measured on a fully automated instrument versus CSF biomarkers for detecting Alzheimer's disease pathology

Noëlle Warmenhoven, MSc *has nothing to disclose.*

Identification of an Alzheimer's Disease Biomarker Signature Using Reproducible Proteomics Data Mining

María Fernanda Zambrano-Astorga *has nothing to disclose.*

4-24-DEV Developing Topics on Dementia Care and Public Health

Neighborhood Spatial Social Polarization and Dementia Disparities Among U.S. Medicare Beneficiaries

Hoda S Abdel Magid, PhD, MHS *has nothing to disclose.*

Sleepless nights: Caregiver burden among DLB patients with nighttime behaviors

Jesse S Cohen, MD *has nothing to disclose.*

Double Burden of Mild Behavioural Impairment and Frailty – Implications for Quality of Life and Cognition in a Southeast Asian Cohort

Ming Hui, Colin Goh, MBBS *has nothing to disclose.*

Association of Neighborhood-Level Disadvantage with Antemortem MRI Brain Volumes in a Multi-site Brain Bank Donor Cohort

Angel Hammond, BS *has nothing to disclose.*

Retinal microvasculature alterations are associated with mild behavioral impairment in a memory clinic population

Yingqi Liao, MSc *has nothing to disclose.*

Establishing a Real-World Data Platform for Dementia Care in Chile: The Red Memoria Viva Electronic Registry “REMEMVER” Initiative

Natalia Pozo Castro, MD *has nothing to disclose.*

Disruptions in circadian rhythm alter amyloid-dependent changes in tau and cognition

Yiwen Rao, MS *has nothing to disclose.*

Population attributable fraction for dementia in American Indians

Astrid M Suchy-Dicey, PhD *has nothing to disclose.*

Machine learning-assisted optimizing dietary intervention against dementia risk

Jin-tai Yu, MD, PhD *has nothing to disclose.*

4-25-FRS-A Nourishing the mind: how diet and gut health shape cognitive aging

Adherence to the MIND diet and longitudinal brain structural changes over a decade: evidence from the Framingham Offspring cohort

Hui Chen, PhD *has nothing to disclose.*

Diet-Driven Metabolite Patterns Link the MIND Diet to Dementia Biomarkers

Diandra N. Denier-Fields, PhD *has nothing to disclose.*

The Gut-Brain Connection: How Age, Sex, and APOE ε4 Influence Probiotic Balance in Early Alzheimer’s Disease

Warnakulasuriya MADB Fernando, PhD *has nothing to disclose.*

bioMIND-A Novel Approach to Integrating Biomarkers in the Diagnostic Workup for Alzheimer’s Disease

Ameya Patwardhan, MBBS, DM *has nothing to disclose.*

Gut Microbiome Diversity as a Mediator Between Life's Essential 8 Adherence and Cognitive Function

Yannick Joel Wadop Ngouongo, PhD *has nothing to disclose.*

4-26-FRS-A Innovative use of statistical models and machine learning to enhance AD clinical trials

Baseline predictions of PACC progression trajectories in preclinical AD improve the precision and power of treatment effect assessments

Viswanath Devanarayan, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai Inc. - Employee/Owner

A Novel Linear B-Spline Mixed Effect Model for Alzheimer's Disease Clinical Study Data

Kun Jin, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Anavex Life Sciences - Employee/Owner

Discussion of Perspectives on Various Innovative Statistical Methodologies for Alzheimer's Disease Clinical Trials

John Lawrence, PhD *has nothing to disclose.*

Primary Endpoint and Analysis Model for Prevention Trials with Participants with Preclinical AD: Lessons Learned from the DIAN-TU Platform Trial

Yan Li, PhD *has nothing to disclose.*

Subgroup Identification in Alzheimer's Disease Trial

Lei Liu, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Adial Pharmaceuticals - Consultant/Advisory Board

Beyond A Single Study Visit: Lesson Learned from the AD Clinical Trials

Jinglin Zhong, PhD *has nothing to disclose.*

4-27-FRS-A Network alterations and aberrant neuronal activity in Alzheimer's disease: novel targets to understand and influence disease progression?

The HOPE4MCI study: AGB101 treatment normalizes aberrant network activity and slows entorhinal cortex atrophy in patients with amnesic mild cognitive impairment due to Alzheimer's Disease who are ApoE-4 non-carriers

Arnold Bakker, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AgeneBio, Inc - Consultant/Advisory Board

Change in functional connectivity strength during rest and encoding is differentially related to Alzheimer's pathology and memory depending on APOE genotype

Larissa Fischer, MSc *has nothing to disclose.*

Specific functional patterns of the locus coeruleus and cognitive decline in preclinical Alzheimer's disease: associations with tau and astrocyte reactivity

Heidi I.L. Jacobs, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Cala Health -

Real-time fMRI neurofeedback normalizes hippocampal hyperactivity and improves memory performance in preclinical Alzheimer's disease

Jessica Peter, PhD *has nothing to disclose.*

Amyloid-induced neuronal hyperactivity and -metabolism are associated with faster tau accumulation in Alzheimer's Disease

Sebastian Roemer-Cassiano, MD *has nothing to disclose.*

Brain connectivity drives tau presence while regional vulnerability drives tau load in Alzheimer's disease

Yu Xiao, PhD *has nothing to disclose.*

3:30-4:15 pm

4-A-GEP Guided Electronic Poster Tour: Peripheral neurovascular biomarkers of Alzheimer's disease and Amyloid Angiopathy: From Brain to Retina to Nose

Retinal vascular metrics are associated with enlarged MRI-visible perivascular spaces in cognitively unimpaired older adults

Edmund Arthur, OD, PhD *has nothing to disclose.*

Impaired Brain to Nasal Turbinates Pathway in Aging Amyloid Positive Subjects Using [1-11C]-Butanol PET Imaging

Samantha A Keil, PhD *has nothing to disclose.*

Monday-106 Intramural Peri Arterial Drainage (IPAD) of peptides from the brain parenchyma and retina

Roxana O. Carare *has nothing to disclose.*

Wednesday-113 Retinal Vascular Pathology in MCI and AD: Links to Cerebral Amyloid Angiopathy and Cognition

Maya Koronyo-Hamaoui, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

NeuroVision Imaging -

4-B-GEP Guided Electronic Poster Tour: Understanding the Role of Nutrition and Metabolism in AD/ABRD: From Cell to Community

Sunday-392 A common genetic variant of IDO1 exacerbates brain hypometabolism and cognitive decline

Christian Limberger, MSc *has nothing to disclose.*

Sunday-606 Creatine to Augment Bioenergetics in Alzheimer's Disease

Matthew K Taylor, PhD *has nothing to disclose.*

Wednesday-801 The MIND diet association with lower microglial inflammation in the hippocampus: A Community-Based Neuropathologic Study

Puja Agarwal, PhD *has nothing to disclose.*

4:15-5:45 pm

4-28-FRS-A Considerations for AD Prevention: Optimising Clinical Trial Design

Exploring Characteristics Predictive of Willingness to Participate in Preclinical Alzheimer's Disease Trials

Adam I Birnbaum, MS *has nothing to disclose.*

Optimizing Clinical Trials for Primary and Secondary Alzheimer's Prevention Studies - A Quantitative Perspective

Suzanne B. Hendrix, Ph.D *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Pentara Corporation - Employee/Owner

How to efficiently move towards primary prevention in sporadic AD

Rema Raman, PhD *has nothing to disclose.*

4-29-FRS-C The Global Neurodegeneration Proteomics Consortium: A Public-private Partnership for Biomarker Discovery & Disease Mechanism Insight

Plasma proteomic profiling of AD, PD and FTD in a large sample of individuals from the global neurodegeneration proteomics consortium (GNPC)

Muhammad Ali, PhD *has nothing to disclose.*

Benchmarking the AI-based diagnostic potential of plasma proteomics for neurodegenerative disease in 17,710 people

Lijun An, PhD *has nothing to disclose.*

APOE4 carriers across neurodegenerative diseases have common systemic biological dysfunction

Caitlin A Finney, PhD *has nothing to disclose.*

An overview and history of the Global Neurodegeneration Proteomics Consortium (GNPC)

Farhad Imam, MD, PhD *has nothing to disclose.*

4-30-CTB-C Case studies in the evaluation, treatment, and monitoring of anti-amyloid therapies

When to stop therapy?

Seong Hye Choi, MD, PhD *has nothing to disclose.*

Implementing amyloid PET into clinical practice

Mary Ellen I. Koran, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

CME Outfitters - Speakers Bureau/Honoraria for non-CME

Lantheus - Non-Mutual funds Stock

Challenging cases in the evaluation of patients for anti-amyloid therapy

Vijay K. Ramanan, MD, PhD *has nothing to disclose.*

Managing ARIA, applying lessons learned from the trials to clinical cases

Melissa Yu, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alzheimer's Association -

AriBio -

Biogen -

Cognition Therapeutics -

Eisai -

Novo Nordisk -

Owkin -

SUVEN -

4-31-FRS-B Anti-Tau Etalnetug (E2814) with Lecanemab Therapy in Individuals with Dominantly Inherited Alzheimer's Disease: A First Look at Baseline Characteristics and Impact of 6-Month Lecanemab Treatment on Amyloid PET and Safety in the DIAN-TU-001 NexGen Trial

Lecanemab in DIAD: 6-Month Amyloid PET Results from the DIAN-TU-001 Trial

Randall J. Bateman, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Biogen, AbbVie, BMS, Novartis, NIH, NINDS/NIA, Centene, Rainwater, Eisai, Eli Lilly, Hoffman-La Roche, CogState, Signant, - Grant/Research Support

C2N Diagnostics -

Eisai, Janssen, Hoffman LaRoche -

Hoffman La-Roche, Biogen, UK Dementia Research Institute, Stanford -

Baseline Imaging Characteristics of Participants in the Phase II/III DIAN-TU-001 Tau NexGen Trial for Dominantly Inherited Alzheimer's Disease

Tammie L.S. Benzinger, MD, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

**Avid Radiopharmaceuticals/Eli Lilly, LMI, Lantheus -
Biogen, Eli Lilly, Eisai, BMS, JNJ, Merck - Consultant/Advisory Board
Hyperfine -**

Baseline Participant Characteristics in the DIAN-TU-001 Trial

Jorge J. Llibre-Guerra, MD, MS *has nothing to disclose.*

DIAN-TU-001 Trial (Tau NexGen) Rationale and Enrollment Experience

Lon S. S. Schneider, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai, Biogen, Biohaven - Grant/Research Support

Eli Lilly/Avid - Grant/Research Support

Neurim, Ltd (Israel), Cognition Therapeutics, Corium, Immunobrain Checkpoint, Ltd (Israel), Alpha-cognition, BioVie, Lexeo, Lighthouse, AC Immune (Suisse), Athira, GW Research (UK, Jazz, USA), Merck, Otsuka (USA), Pharmatrophix, Linus Health, Lundbeck, No -
Consultant/Advisory Board

Roche/Genentech - Grant/Research Support

UC San Diego ADCS - Grant/Research Support

Washington University, St. Louis/ NIA DIAN-TU - Grant/Research Support

Safety of Lecanemab After 6-Month Treatment in the DIAN-TU-001 Trial

Jin Zhou, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eisai - Employee/Owner

4-32-PER-B The current state of registries for participant recruitment in dementia research and the future direction to fast-track dementia research: A global perspective

Fast-tracking dementia research: the comparison between Join Dementia Research, StepUp for Dementia Research and TrialMatch

Yun-Hee Jeon, PhD, MN, BHSc (Nurs) *has nothing to disclose.*

The current state of registries for participant recruitment in dementia research and the future direction to fast-track dementia research globally: perspectives from the Alzheimer's Prevention Registry programs

Jessica B. Langbaum, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Eli Lilly - Grant/Research Support

The Brain Health Registry: Facilitating AD and aging clinical research through participant referral to clinical studies

Rachel L. Nosheny, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Genentech, Inc - Grant/Research Support

CARE Registry: An update & plans to further expand the meaningful inclusion of Asian American, Native Hawaiian, and Pacific Islander populations in Alzheimer's disease and related dementias research

Van Ta Park, PhD, MPH *has nothing to disclose.*

The Dutch Brain Research Registry's progress and developments

Marissa D. Zwan, PhD *has nothing to disclose.*

4-33-PER-C Transforming Dementia Care: An Introduction to the GUIDE Model

Setting the Stage: The Role of Navigation in Dementia Care

Katherine Evans *has nothing to disclose.*

Bringing It All Together: Resources and Next Steps Dementia Care Coordination Program Implementation Evaluation

Nancy A Hodgson, PhD, RN, FAAN *has nothing to disclose.*

Perspectives from a GUIDE Practitioner

Hillary Lum, MD, PhD *has nothing to disclose.*

4-34-FRS-A Global perspectives on implementation science in dementia research: Exploring diverse approaches and challenges in different healthcare systems and policy settings.

Strategies for Enhancing Participant Recruitment and Retention in Dementia Research in Africa: Experience from the African Dementia Consortium.

Rufus O. Akinyemi, MBBS, MSc, PhD *has nothing to disclose.*

Exploring the stakeholder-informed adaptation of a goal-based psychosocial intervention for people with dementia and their caregivers in diverse services and communities in the UK.

Jessica Budgett *has nothing to disclose.*

Achieving Dissemination and Implementation Success in Dementia Care: A Consideration of Methodological Strategies

Joseph Gaugler, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AIM-AHEAD - Consultant/Advisory Board

AmericaSociety for Public Administration, Zhejiang University, China - Speakers

Bureau/Honoraria for non-CME

Benjamin Rose Institute - Speakers Bureau/Honoraria for non-CME

Care Virtue - Consultant/Advisory Board

Centers for Disease Control and Prevention - Grant/Research Support

Cornell University - Speakers Bureau/Honoraria for non-CME

Department of Defense - Grant/Research Support

Department of Justice - Consultant/Advisory Board

EMC2 - Consultant/Advisory Board

HealthCare Interactive, Inc. - Consultant/Advisory Board

Indiana University-Bloomington - Speakers Bureau/Honoraria for non-CME

Iowa Department of Health - Speakers Bureau/Honoraria for non-CME

Jewish Family Services of St. Paul, MN - Consultant/Advisory Board
Johns Hopkins University -
Kansas University Medical Center - Speakers Bureau/Honoraria for non-CME
National Institutes of Health/National Institute on Aging - Grant/Research Support
The Alzheimer's Association - Consultant/Advisory Board
The Villages - Consultant/Advisory Board
UMass AITC - Speakers Bureau/Honoraria for non-CME
University of California Irvine - Consultant/Advisory Board
University of California San Francisco - Consultant/Advisory Board
University of Michigan - Speakers Bureau/Honoraria for non-CME
Utah NRMN - Consultant/Advisory Board
Vista Prairies - Consultant/Advisory Board
Yale University - Speakers Bureau/Honoraria for non-CME

Advancing dementia care through implementation science: global and Australian perspectives

Anita M Y Goh, BSc, DPsych *has nothing to disclose.*

Biobehavioral Age Gaps as a Global Index to Assess Disparities and the Exposome in Accelerated Aging Across 40 Countries

Agustin Ibanez, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
AA/NIH/ANID - Grant/Research Support

Application of Implementation Science Principles in LMIC Settings – South Asian Exemplars

Iracema Leroi, MD, FRCPC, MRCPsych *has nothing to disclose.*

4-35-FRS-A The rehabilitation of gamma-secretase as a drug target in Alzheimer's Disease

The whereabouts of presenilins: from location to mechanisms

Wim Annaert, PhD *has nothing to disclose.*

The metastability of γ -secretases as foundation for AD onset and prevention

Lucia Chávez-Gutiérrez, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
Roche - Consultant/Advisory Board
TRIM - Grant/Research Support

Gamma-secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease

Jasmeer P. Chhatwal, MD, PhD *has nothing to disclose.*

The A431E PSEN1 mutation arising as a founder effect in Jalisco State in Mexico: clinical features, imaging, and neuropathological findings

John M Ringman, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*
AltaMed - Grant/Research Support
Avid Pharmaceuticals - Grant/Research Support

Gene therapy for presenilin mutation carriers

Inmaculada Sanjuan Ruiz, PhD *has nothing to disclose.*

Clinical phenotype and neuropathological correlates in autosomal dominantly inherited familial Alzheimer's disease: insights from a UK case series

Natalie S Ryan, PhD MRCP *has nothing to disclose.*

4-36-FRS-B Awareness of Cognitive Function across the Alzheimer's disease spectrum: biological mechanisms, diagnostic, and prognostic clinical value

Leveraging informant perspectives to evaluate cognitive decline: Key characteristics of ideal informants

Federica Cacciamani, PhD *has nothing to disclose.*

Plasma pTau and GFAP are associated with subjective cognitive decline and memory concerns in the remote, digital Brain Health Registry cohort.

Joseph Eichenbaum *has nothing to disclose.*

Distinct awareness trajectories and plasma p-tau₂₁₇ accumulation over time in preclinical Alzheimer's disease

David López-Martos, MSc *has nothing to disclose.*

Diagnostic blind spot in clinical manifestations: anosognosia trajectory in preclinical Alzheimer's is linked to core pathophysiology, astrocytic reactivity, and structural changes in cognitive control and self-referential brain regions

Gonzalo Sánchez-Benavides, PhD *has nothing to disclose.*

Functional connectivity dysregulation across the awareness continuum in Alzheimer's Disease: from hypergnosia to anosognosia

Manuela Tondelli, MD, PhD *has nothing to disclose.*

Thursday, July 31, 2025, AAIC Disclosures

9:00-9:45 am

5-4-FRS-A Early Career Researchers in Community Engagement

Efficacy of interventions to treat and prevent Alzheimer's disease in individuals with Down syndrome: A meta-analysis and systematic review

Emily E Munn, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Therabody - Grant/Research Support

Sunday-006 Exploring how individuals with dementia self-cue while completing three household tasks

Christina Commisso, HBSc *has nothing to disclose.*

Sunday-675 Potential Mechanisms Explaining Effects of Spiritual Practices on Cognitive Aging: A Systematic Review and Conceptual Model

Katherine Carroll Britt, PhD, MSN, RN *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

BrainCheck, Inc. - Consultant/Advisory Board

5-5-LPR Novel biomarkers

Digital Voice as an Alternative Screening Tool to the Montreal Cognitive Assessment

Hamzah Anan *has nothing to disclose.*

Low CSF APP refines diagnosis for p-tau negative Alzheimer-like dementia

Pratishtha Chatterjee, PhD *has nothing to disclose.*

Accelerometer-measured physical activity, sedentary behavior, and incident neuropsychiatric diseases: a large prospective cohort study of 73411 participants

Wu Jiayi *has nothing to disclose.*

Perivascular Spaces as Early Indicators of Alzheimer's Pathology and Cognitive Impairment in a Southeast Asian Cohort: Insights from the BIOCIS Study

Justin Jit Hong Ong *has nothing to disclose.*

Associations between plasma pTau217, cognitive impairment, and synaptic density in AD vulnerable brain regions

Kao Lee Yang, MA *has nothing to disclose.*

5-6-FRS-D Vascular contributions to cognitive impairment II

Multimorbidity and Cognitive Trajectories in Resource-Limited Settings: Real-World Evidence from a Brazilian Public Memory Clinic

Fernando Jacob Lazzaretti *has nothing to disclose.*

Disadvantaged neighbourhoods, modifiable risk factors, and cerebral small vessel disease in healthy midlife adults: the PREVENT Dementia study

Audrey Low, PhD *has nothing to disclose.*

Impact of Cerebrovascular Disease on Gender-Specific Cognitive and Biomarker Profiles: Insights from the Southeast Asian BIOCIS Cohort

Pricilia Tanoto, MD *has nothing to disclose.*

5-7-LPR Multi-Level Social Determinants and Brain Health

Yarning to understand locally tailored dementia prevention and care for Australian Aboriginal and Torres Strait Islander peoples

Antonia Jean Clarke, BSc (Hons), LLB (Hons), MBBS (Hons) *has nothing to disclose.*

Baseline Results Investigate APOE-Memory Connection in Latin-American Population at Risk for Dementia - LatAm-FINGERS Initial Insights

Clarisse Vasconcelos Friedlaender, MSc *has nothing to disclose.*

Associations of Mid-to-Late Life Neighborhood Disadvantage with Cognitive Trajectories and Dementia Outcomes in the Health and Retirement Study

Adrienne R.S. Lee, PhD, MPH *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Linus Health Inc -

APOE- ε4, social determinants of health and Alzheimer's Disease pathology and dementia: findings from the Biobank for Aging Studies

Naomi Vidal-Ferreira, PhD *has nothing to disclose.*

Associations of social determinants of health (SDOH) with dementia and mild cognitive impairment (MCI), the HABS-HD Study

Shanshan Wang, MBBS *has nothing to disclose.*

Wednesday-756 The Effect of Social Determinants of Health on Cognitive Resilience to Alzheimer's Disease, Determined by Plasma p-tau217 in the Prospective INDE Cohort in Thailand: A Story from a Middle-Income Country

Thanapoom Taweephon, MD *has nothing to disclose.*

5-8-FRS-D Early Phase Studies Exploring Diverse Mechanisms II

Topline results from Phase 1/2 AAV gene therapy (LX1001) in APOE4/4 homozygotes with Alzheimer's disease

Kim G Johnson, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

ALZ-NET -

Annovis Bio -

Athira -

Cleveland Clinic -

Cognitive Therapeutics -

Eisai - Speakers Bureau/Honoraria for non-CME

Lexeo Therapeutics -

Lilly - Consultant/Advisory Board

Peer View CME -

University of Southern California -

Development of small-molecule based human 20S Proteasome Activators: A novel therapeutic target to combat amyloid plaques in Alzheimer's disease

Poonam Rani, PhD *has nothing to disclose.*

Phase IIb/III ATTENTION-AD Study: Over Three Years of Continuous Treatment with Oral Blarcamesine Continues to Significantly Benefit Early Alzheimer's Disease Patients

Marwan N. Sabbagh, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Alzheimer's Drug Discovery Foundation - Grant/Research Support

Athira, Lighthouse Pharmaceuticals - Ownership/Stock options

EIP Pharma/CervoMed -

Eisai, Lilly, Synaptogenix, NeuroTherapia, Signant Health, Novo Nordisk, Anavex, Cognito Therapeutics, GSK, Abbvie, Alzheon. - Consultant/Advisory Board

Lewy Body Dementia Association - Grant/Research Support

National Institutes of Health (NIH) - Grant/Research Support

5-9-LPR Diabetes and Dementia

Dapagliflozin restores odor-induced functional integration of POC circuit, but not local olfactory neural activation in patients with type 2 diabetes: a 16-week randomized parallel comparative study

Xin Li *has nothing to disclose.*

Effects of oral Ketone Ester on brain metabolism and cognition: a randomized controlled trial

Apostolos Manolopoulos, MD *has nothing to disclose.*

Sodium-glucose cotransporter-2 inhibitor initiation and incident dementia in heart failure with diabetes: a population-based cohort study

Che-Yuan Wu, BSc *has nothing to disclose.*

Wednesday-420 Investigating the Association of Frailty Score and Diabetes with Relative Brain Age : Insights from the UK Biobank

Mahboubeh Motaghi, PhD Candidate, M.Sc., B.Sc *has nothing to disclose.*

Wednesday-425 Brain Changes Associated with HbA1c and Systolic Blood Pressure Observed Using NODDI Contribute to Prediction of Cognition

Robert I. Reid, PhD *has nothing to disclose.*

Wednesday-524 The association of glycemic dysregulation with cognitive decline and structural MRI brain volumes in The Maastricht Study – A role for peripheral inflammation?

Veerle van Gils, PhD *has nothing to disclose.*

10:00-11:30 am

5-13-FRS-C Advancing Translational Success by Enhancing Predictive Validity in Neurodegenerative Diseases

Combining humanized mice, neurochemical, imaging, and cognitive biomarkers for drug discovery in mice.

Anoosha Attaran, PhD *has nothing to disclose.*

Protein misfolding-specific epitope identification for passive and active immunotherapy of neurodegenerative diseases

Neil R Cashman *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

ProMIS Neurosciences - Employee/Owner

p75 neurotrophin receptor: a prototype therapeutic target modulating fundamental mechanisms of degeneration and glial function in Alzheimer's and related dementias

Frank Longo *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Pharmatrophix -

Predicting differential effects of sex on therapeutic benefit and limitations in Alzheimer's disease drug development using animal models

Stacey J Sukoff Rizzo, PhD *has nothing to disclose.*

5-15-FRS-C Improving Dementia Detection in Primary Care: Learnings from Three Embedded, Pragmatic Clinical Trials

Evaluating Targeted Dementia Screening of High-Risk Patients in Primary Care: Preliminary Results from the electronic health record Risk of Alzheimer's and Dementia Assessment Rule (eRADAR) pragmatic randomized trial

Deborah E Barnes, PhD, MPH *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Linus Health - Ownership/Stock options

Together Senior Health - Ownership/Stock options

Digital Detection of Dementia (D Cubed) Trials

Malaz Boustani, MD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

ACADIA - Consultant/Advisory Board
Biogen - Consultant/Advisory Board
Blue Agilis - Ownership/Stock options
DigiCare Realized - Ownership/Stock options
Eisai - Speakers Bureau/Honoraria for non-CME
Lilly - Speakers Bureau/Honoraria for non-CME
Merck - Consultant/Advisory Board
Mozyne Health - Ownership/Stock options
My Shift Also Known as ReseUP - Ownership/Stock options
PPHM - Ownership/Stock options

Discussant-Improving Dementia Detection in Primary Care: Learnings from Three Embedded, Pragmatic Clinical Trials

Joseph Gaugler, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

AIM-AHEAD - Consultant/Advisory Board
AmericaSociety for Public Administration, Zhejiang University, China - Speakers Bureau/Honoraria for non-CME
Benjamin Rose Institute - Speakers Bureau/Honoraria for non-CME
Care Virtue - Consultant/Advisory Board
Centers for Disease Control and Prevention - Grant/Research Support
Cornell University - Speakers Bureau/Honoraria for non-CME
Department of Defense - Grant/Research Support
Department of Justice - Consultant/Advisory Board
EMC2 - Consultant/Advisory Board
HealthCare Interactive, Inc. - Consultant/Advisory Board
Indiana University-Bloomington - Speakers Bureau/Honoraria for non-CME
Iowa Department of Health - Speakers Bureau/Honoraria for non-CME
Jewish Family Services of St. Paul, MN - Consultant/Advisory Board
Johns Hopkins University -
Kansas University Medical Center - Speakers Bureau/Honoraria for non-CME
National Institutes of Health/National Institute on Aging - Grant/Research Support
The Alzheimer's Association - Consultant/Advisory Board
The Villages - Consultant/Advisory Board
UMass AITC - Speakers Bureau/Honoraria for non-CME
University of California Irvine - Consultant/Advisory Board
University of California San Francisco - Consultant/Advisory Board
University of Michigan - Speakers Bureau/Honoraria for non-CME
Utah NRMN - Consultant/Advisory Board
Vista Prairies - Consultant/Advisory Board
Yale University - Speakers Bureau/Honoraria for non-CME

1) Leveraging the NIH Toolbox for Early Detection of Cognitive Impairment in Primary Care: The Toolbox Detect Trial

Stephanie Ruth Young, PhD *has nothing to disclose.*

5-16-FRS-A Harnessing the Power of Collaborative Data Sharing and Research: Progress and Existing Barriers

Harmonization and resulting ease with which researchers can discover and combine datasets; federated approaches

Sarah Bauermeister, PhD, CPsychol *has nothing to disclose.*

The Scottish BioHermes Data Challenge: democratising dementia data access

Kalliopi Mavromati *has nothing to disclose.*

Gateway to Global Aging Data: Enabling Comparative Research on Aging, Health, and Environment

Drystan Phillips *has nothing to disclose.*

AD Knowledge Portal, ELITE Portal and Agora: Resources that empower the research community to find, access, and re-use data and tools related to dementia and ageing

Susheel Varma, PhD FBCS *has nothing to disclose.*

Enhancing dataset discovery and interoperability, and mobilizing the community via challenges

Julie Wood *has nothing to disclose.*

Enhancing interoperability features in the Global Alzheimer's Association Interactive Network

Cally Xiao, PhD *has nothing to disclose.*

5-17-FRS-A Pathways Into/Out of the brain. Relevance to Alzheimer's disease

Sustained meningeal lymphatic vessel atrophy or expansion does not alter Alzheimer's disease-related amyloid pathology

Salli Antila, PhD *has nothing to disclose.*

Changes in adrenergic and cholinergic receptors on human cerebral vessels. Implications for new therapeutic strategies in Alzheimer's Disease

Roxana O. O Carare, MD, PhD *has nothing to disclose.*

Non-contrast MRI of blood-brain barrier, arterial vessel integrity, glymphatic function in ADRD and ARIA

Hanzhang Lu, PhD *has nothing to disclose.*

Vascular and immune epigenetic mechanisms underlying Alzheimer's disease

Alexi Nott, PhD *has nothing to disclose.*

A 24 hour neuroimaging protocol to track solute transport from blood to the CSF as a surrogate for protein clearance

Swati Rane Levendovszky, PhD *has nothing to disclose.*

Ins and Outs of Intrathecal Drug Delivery

Ajay Verma, MD, PhD *has nothing to disclose.*

5-18-FRS-B United States Cost of Dementia Model (USCDM)

Impact of dementia caregiving on the labor force participation and lifetime earning of middle age adults

Manying (Mandy) Cui *has nothing to disclose.*

Costs of dementia: Comprehensive Estimates from U.S. Cost of Dementia Model (USCDM)

Hanke Heun-Johnson, PhD *has nothing to disclose.*

Disaggregating medical costs due to dementia

Johanna Thunell, PhD *has nothing to disclose.*

Voices from the Community: New insights into costs of dementia from persons with lived experience, public health leaders and health care providers

Lycia Tramujas Vasconcellos Neumann, PhD, MPA *has nothing to disclose.*

Opportunities for using the USCDM for impact

Bryan Tysinger, PhD *has nothing to disclose.*

10:30-11:30 am

5-14-FRS-A Biomarkers and Neuropathology

Unveiling the distinct roles of p-tau, iron and MAOB in neurobiological basis of F18-flortaucipir signal with voxel-to-voxel histology to PET analysis in different tauopathies

Yuheng Chen, BA *has nothing to disclose.*

Lower Antemortem [¹⁸F]flortaucipir PET retention in Males and Older Individuals is Explained by Lower Postmortem Tau Tangle Density

Emma M. Coomans, PhD *has nothing to disclose.*

Biofluid-based biomarkers to predict onset of Alzheimer's disease neuropathology

Douglas R. Galasko, MD *has nothing to disclose.*

MRI measures of neuropathology in neurodegenerative disease

Laura E. Jonkman, PhD *has nothing to disclose.*

Differential performance of plasma p-tau₂₁₇ in detecting intermediate vs high Alzheimer's disease neuropathologic change

Stamatia Karagianni, MSc *has nothing to disclose.*

Tau-PET overlap index correlates with neuropathology findings in early-Braak stage

Seokbeen Lim, PhD *has nothing to disclose.*

11:45-1:00 pm

5-10-PL Plenary Session

Prevention of dementia: a necessary worldwide agenda

Gill Livingston, MD *has nothing to disclose.*

5-10-PL Plenary Session

Brain Resilience: Understanding Brain Aging and Neurodegeneration

Tony Wyss-Coray, PhD *has had a personal financial relationship in the last 12 months with the following organization(s) whose products or services will be mentioned in this presentation:*

Tealomics - Ownership/Stock options